

Louisa J Degenhardt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6469438/publications.pdf>

Version: 2024-02-01

687
papers

176,518
citations

511
128
h-index

46
399
g-index

702
all docs

702
docs citations

702
times ranked

165003
citing authors

#	ARTICLE	IF	CITATIONS
1	Changes in illicit drug use and markets with the COVID-19 pandemic and associated restrictions: findings from the Ecstasy and Related Drugs Reporting System, 2016-20. <i>Addiction</i> , 2022, 117, 182-194.	3.3	31
2	Use of pharmacological and nonpharmacological treatments for chronic noncancer pain among people using opioids: a longitudinal cohort study. <i>Pain</i> , 2022, 163, 1049-1059.	4.2	2
3	Comorbidity between mood and substance-related disorders: A systematic review and meta-analysis. <i>Australian and New Zealand Journal of Psychiatry</i> , 2022, 56, 757-770.	2.3	14
4	Economic analysis of out-of-pocket costs among people in opioid agonist treatment: A cross-sectional survey in three Australian jurisdictions. <i>International Journal of Drug Policy</i> , 2022, 99, 103472.	3.3	11
5	Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence. <i>International Journal of Drug Policy</i> , 2022, 100, 103492.	3.3	22
6	Modeling the population-level impact of opioid agonist treatment on mortality among people accessing treatment between 2001 and 2020 in New South Wales, Australia. <i>Addiction</i> , 2022, 117, 1338-1352.	3.3	11
7	Exposure to childhood trauma increases risk of opioid use disorder among people prescribed opioids for chronic non-cancer pain. <i>Drug and Alcohol Dependence</i> , 2022, 230, 109199.	3.2	9
8	The contribution of unstable housing to HIV and hepatitis C virus transmission among people who inject drugs globally, regionally, and at country level: a modelling study. <i>Lancet Public Health</i> , The, 2022, 7, e136-e145.	10.0	14
9	Increase in Depression and Anxiety Among Australian Gay and Bisexual Men During COVID-19 Restrictions: Findings from a Prospective Online Cohort Study. <i>Archives of Sexual Behavior</i> , 2022, 51, 355-364.	1.9	10
10	Self-harm and suicide during and after opioid agonist treatment among primary care patients in England: a cohort study. <i>Lancet Psychiatry</i> , the, 2022, 9, 151-159.	7.4	6
11	Trends in comorbid opioid and stimulant use disorders among Veterans receiving care from the Veterans Health Administration, 2005-2019. <i>Drug and Alcohol Dependence</i> , 2022, 232, 109310.	3.2	11
12	Mood and Anxiety Symptoms in Persons Taking Prescription Opioids: A Systematic Review with Meta-Analyses of Longitudinal Studies. <i>Pain Medicine</i> , 2022, 23, 1442-1456.	1.9	14
13	Examining the cost and impact of dosing fees among clients in opioid agonist treatment: Results from a cross-sectional survey of Australian treatment clients. <i>Drug and Alcohol Review</i> , 2022, 41, 841-850.	2.1	7
14	State-Level Prevalence and Associates of Opioid Dependence in the USA. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 3825.	2.6	4
15	Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 426-445.	8.1	50
16	The impact of opioid agonist treatment on fatal and non-fatal drug overdose among people with a history of opioid dependence in NSW, Australia, 2001-2018: Findings from the OATS retrospective linkage study. <i>Drug and Alcohol Dependence</i> , 2022, 236, 109464.	3.2	7
17	Patterns and correlates of patient-reported helpfulness of treatment for common mental and substance use disorders in the WHO World Mental Health Surveys. <i>World Psychiatry</i> , 2022, 21, 272-286.	10.4	16
18	Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study. <i>International Journal of Drug Policy</i> , 2022, 105, 103706.	3.3	14

#	ARTICLE	IF	CITATIONS
19	Self-reported challenges obtaining ongoing prescription opioids among Australians with chronic non-cancer pain. <i>International Journal of Drug Policy</i> , 2022, 105, 103708.	3.3	2
20	The impact of opioid agonist treatment on hospitalisations for injecting-related diseases among an opioid dependent population: A retrospective data linkage study. <i>Drug and Alcohol Dependence</i> , 2022, 236, 109494.	3.2	12
21	Trends in methamphetamine use, markets and harms in Australia, 2003â€“2019. <i>Drug and Alcohol Review</i> , 2022, 41, 1041-1052.	2.1	17
22	A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study. <i>Viruses</i> , 2022, 14, 1555.	3.3	7
23	Prevalence and factors associated with hospitalisation for bacterial skin infections among people who inject drugs: The ETHOS Engage Study. <i>Drug and Alcohol Dependence</i> , 2022, 237, 109543.	3.2	6
24	Trends in opioid analgesic utilisation among people with a history of opioid dependence. <i>Drug and Alcohol Dependence</i> , 2022, 238, 109548.	3.2	3
25	Can a new formulation of opiate agonist treatment alter stigma?: Place, time and things in the experience of extended-release buprenorphine depot. <i>International Journal of Drug Policy</i> , 2022, 107, 103788.	3.3	18
26	Prevalence of mental disorders among people with opioid use disorder: A systematic review and meta-analysis. <i>Drug and Alcohol Dependence</i> , 2022, 238, 109551.	3.2	31
27	Data Resource Profile: The Opioid Agonist Treatment and Safety (OATS) Study, New South Wales, Australia. <i>International Journal of Epidemiology</i> , 2021, 49, 1774-1775.	1.9	10
28	Association between opioid agonist therapy use and HIV testing uptake among people who have recently injected drugs: a systematic review and meta-analysis. <i>Addiction</i> , 2021, 116, 1664-1676.	3.3	9
29	Feasibility and acceptability of take-home naloxone for people released from prison in New South Wales, Australia. <i>Drug and Alcohol Review</i> , 2021, 40, 98-108.	2.1	3
30	Substantial Decline in Use of HIV Preexposure Prophylaxis Following Introduction of COVID-19 Physical Distancing Restrictions in Australia: Results From a Prospective Observational Study of Gay and Bisexual Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 22-30.	2.1	53
31	A trial of Criminal Infringement Notices as an alternative to criminal penalties for illicit drug offences in New South Wales, Australia: Estimated savings. <i>Drug and Alcohol Review</i> , 2021, 40, 93-97.	2.1	4
32	Hospitalisations for non-fatal overdose among people with a history of opioid dependence in New South Wales, Australia, 2001â€“2018: Findings from the OATS retrospective cohort study. <i>Drug and Alcohol Dependence</i> , 2021, 218, 108354.	3.2	5
33	High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia. <i>Journal of Hepatology</i> , 2021, 74, 293-302.	3.7	27
34	All-cause and cause-specific mortality among people with regular or problematic cocaine use: a systematic review and meta-analysis. <i>Addiction</i> , 2021, 116, 725-742.	3.3	21
35	The Lancet Public Health Commission on gambling. <i>Lancet Public Health</i> , The, 2021, 6, e2-e3.	10.0	22
36	Prevalence of childhood maltreatment among people with opioid use disorder: A systematic review and meta-analysis. <i>Drug and Alcohol Dependence</i> , 2021, 219, 108459.	3.2	26

#	ARTICLE	IF	CITATIONS
37	Trends in cocaine use, markets and harms in Australia, 2003â€“2019. Drug and Alcohol Review, 2021, 40, 946-956.	2.1	15
38	Genome-wide association study of phenotypes measuring progression from first cocaine or opioid use to dependence reveals novel risk genes. Exploration of Medicine, 2021, 2, 60-73.	1.5	6
39	Trends in treatment episodes for methamphetamine smoking and injecting in Australia, 2003â€“2019. Drug and Alcohol Review, 2021, 40, 1281-1286.	2.1	12
40	The next wave? Mental health comorbidities and patients with substance use disorders in under-resourced and rural areas. Journal of Substance Abuse Treatment, 2021, 121, 108189.	2.8	12
41	Retention of opioid agonist treatment prescribers across New South Wales, Australia, 2001â€“2018: Implications for treatment systems and potential impact on client outcomes. Drug and Alcohol Dependence, 2021, 219, 108464.	3.2	10
42	Variations in Longâ€term Opioid Therapy Definitions: A Systematic Review of Observational Studies Using Routinely Collected Data (2000â€“2019). British Journal of Clinical Pharmacology, 2021, 87, 3706-3720.	2.4	5
43	International Association for the Study of Pain Presidential Task Force on Cannabis and Cannabinoid Analgesia: research agenda on the use of cannabinoids, cannabis, and cannabis-based medicines for pain management. Pain, 2021, 162, S117-S124.	4.2	33
44	Pharmaceutical Opioid Use Patterns and Indicators of Extramedical Use and Harm in Adults With Chronic Noncancer Pain, 2012-2018. JAMA Network Open, 2021, 4, e213059.	5.9	4
45	Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis. Lancet Psychiatry, 2021, 8, 301-309.	7.4	20
46	Estimating the risk of suicide associated with mental disorders: A systematic review and meta-regression analysis. Journal of Psychiatric Research, 2021, 137, 242-249.	3.1	76
47	The effect of person, treatment and prescriber characteristics on retention in opioid agonist treatment: a 15â€year retrospective cohort study. Addiction, 2021, 116, 3139-3152.	3.3	14
48	Opportunities to Enhance Linkage to Hepatitis C Care Among Hospitalized People With Recent Drug Dependence in New South Wales, Australia: A Population-based Linkage Study. Clinical Infectious Diseases, 2021, 73, 2037-2044.	5.8	9
49	Alcohol use among young Australian adults in Mayâ€“June 2020 during the COVIDâ€19 pandemic: a prospective cohort study. Addiction, 2021, 116, 3398-3407.	3.3	34
50	Big data and predictive modelling for the opioid crisis: existing research and future potential. The Lancet Digital Health, 2021, 3, e397-e407.	12.3	21
51	Gender differences in the supply of alcohol to adolescent daughters and sons. American Journal of Drug and Alcohol Abuse, 2021, 47, 508-520.	2.1	4
52	Patterns of smoking and injecting methamphetamine and their association with health and social outcomes. Drug and Alcohol Review, 2021, 40, 1256-1265.	2.1	10
53	Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence. JAMA Psychiatry, 2021, 78, 979.	11.0	244
54	Unintentional and intentional drug poisoning deaths, Australia, 2012â€“2016: Drug pattern profile and demographic characteristics. Drug and Alcohol Dependence, 2021, 229, 109112.	3.2	6

#	ARTICLE	IF	CITATIONS
55	Global, regional, and national sex-specific burden and control of the HIV epidemic, 1990â€“2019, for 204 countries and territories: the Global Burden of Diseases Study 2019. <i>Lancet HIV</i> , 2021, 8, e633-e651.	4.7	56
56	Using administrative data to predict cessation risk and identify novel predictors among new entrants to opioid agonist treatment. <i>Drug and Alcohol Dependence</i> , 2021, 228, 109091.	3.2	4
57	Hepatitis C virus cascade of care among people who inject drugs in Australia: Factors associated with testing and treatment in a universal healthcare system. <i>Drug and Alcohol Dependence</i> , 2021, 228, 109050.	3.2	9
58	Clinical correlates and outcomes associated with pregabalin use among people prescribed opioids for chronic nonâ€cancer pain: A fiveâ€year prospective cohort study. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3092-3104.	2.4	9
59	Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e69-e78.	5.8	43
60	Association Between Opioid Agonist Therapy and Testing, Treatment Uptake, and Treatment Outcomes for Hepatitis C Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2021, 73, e107-e118.	5.8	39
61	General risks of harm with cannabinoids, cannabis, and cannabis-based medicine possibly relevant to patients receiving these for pain management: an overview of systematic reviews. <i>Pain</i> , 2021, 162, S80-S96.	4.2	32
62	Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: findings from a crossâ€sectional study in three Australian cities. <i>Addiction</i> , 2021, 116, 1482-1494.	3.3	3
63	Perceived helpfulness of treatment for alcohol use disorders: Findings from the World Mental Health Surveys. <i>Drug and Alcohol Dependence</i> , 2021, 229, 109158.	3.2	3
64	Previous disorders and depression outcomes in individuals with 12-month major depressive disorder in the World Mental Health surveys. <i>Epidemiology and Psychiatric Sciences</i> , 2021, 30, e70.	3.9	3
65	The Medicines Intelligence Centre of Research Excellence: Co-creating real-world evidence to support the evidentiary needs of Australian regulators and payers.. <i>International Journal of Population Data Science</i> , 2021, 6, .	0.1	1
66	Development of a Brief Patient-Administered Screening Tool for Prescription Opioid Dependence for Primary Care Settings. <i>Pain Medicine</i> , 2020, 21, e79-e88.	1.9	8
67	The epidemiology of alcohol use disorders cross-nationally: Findings from the World Mental Health Surveys. <i>Addictive Behaviors</i> , 2020, 102, 106128.	3.0	108
68	Prevalence of Injecting Drug Use and Coverage of Interventions to Prevent HIV and Hepatitis C Virus Infection Among People Who Inject Drugs in Canada. <i>American Journal of Public Health</i> , 2020, 110, 45-50.	2.7	44
69	Frequency of healthâ€care utilization by adults who use illicit drugs: a systematic review and metaâ€analysis. <i>Addiction</i> , 2020, 115, 1011-1023.	3.3	88
70	Opioid use disorder. <i>Nature Reviews Disease Primers</i> , 2020, 6, 3.	30.5	278
71	All-Cause and Cause-Specific Mortality Among People Using Extramedical Opioids. <i>JAMA Psychiatry</i> , 2020, 77, 493.	11.0	83
72	Correlates of indicators of potential extraâ€medical opioid use in people prescribed opioids for chronic nonâ€cancer pain. <i>Drug and Alcohol Review</i> , 2020, 39, 128-134.	2.1	7

#	ARTICLE	IF	CITATIONS
73	Opioid use and harms associated with a sustained-release tapentadol formulation: A post-marketing surveillance study. <i>Drug and Alcohol Dependence</i> , 2020, 206, 107697.	3.2	10
74	Associations between national development indicators and the age profile of people who inject drugs: results from a global systematic review and meta-analysis. <i>The Lancet Global Health</i> , 2020, 8, e76-e91.	6.3	19
75	Depression, post-traumatic stress disorder, suicidality and self-harm among people who inject drugs: A systematic review and meta-analysis. <i>Drug and Alcohol Dependence</i> , 2020, 207, 107793.	3.2	44
76	Biomedical HIV Protection Among Gay and Bisexual Men Who Use Crystal Methamphetamine. <i>AIDS and Behavior</i> , 2020, 24, 1400-1413.	2.7	25
77	Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia. <i>Addiction</i> , 2020, 115, 1295-1305.	3.3	46
78	Frequency of injecting among people who inject drugs: A systematic review and meta-analysis. <i>International Journal of Drug Policy</i> , 2020, 76, 102619.	3.3	21
79	Parental supply of sips and whole drinks of alcohol to adolescents and associations with binge drinking and alcohol-related harms: A prospective cohort study. <i>Drug and Alcohol Dependence</i> , 2020, 215, 108204.	3.2	16
80	Injecting risk behaviours amongst people who inject drugs: A global multi-stage systematic review and meta-analysis. <i>International Journal of Drug Policy</i> , 2020, 84, 102866.	3.3	17
81	A large-scale genome-wide association study meta-analysis of cannabis use disorder. <i>Lancet Psychiatry</i> , 2020, 7, 1032-1045.	7.4	200
82	Physical Distancing Due to COVID-19 Disrupts Sexual Behaviors Among Gay and Bisexual Men in Australia: Implications for Trends in HIV and Other Sexually Transmissible Infections. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 309-315.	2.1	98
83	Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1204-1222.	13.7	7,664
84	Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1223-1249.	13.7	3,928
85	Perceived helpfulness of treatment for posttraumatic stress disorder: Findings from the World Mental Health Surveys. <i>Depression and Anxiety</i> , 2020, 37, 972-994.	4.1	12
86	Profile and correlates of injecting-related injuries and diseases among people who inject drugs in Australia. <i>Drug and Alcohol Dependence</i> , 2020, 216, 108267.	3.2	13
87	Risk factors for indicators of opioid-related harms amongst people living with chronic non-cancer pain: Findings from a 5-year prospective cohort study. <i>EClinicalMedicine</i> , 2020, 28, 100592.	7.1	16
88	Estimating the contribution of stimulant injection to HIV and HCV epidemics among people who inject drugs and implications for harm reduction: A modeling analysis. <i>Drug and Alcohol Dependence</i> , 2020, 213, 108135.	3.2	20
89	Integrating HIV pre-exposure prophylaxis and harm reduction among men who have sex with men and transgender women to address intersecting harms associated with stimulant use: a modelling study. <i>Journal of the International AIDS Society</i> , 2020, 23, e25495.	3.0	14
90	The contribution of methamphetamine use to crime: Evidence from Australian longitudinal data. <i>Drug and Alcohol Dependence</i> , 2020, 216, 108262.	3.2	15

#	ARTICLE	IF	CITATIONS
91	Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study. <i>BMJ Open</i> , 2020, 10, e034389.	1.9	9
92	All-Cause and Overdose Mortality Risk Among People Prescribed Opioids: A Systematic Review and Meta-analysis. <i>Pain Medicine</i> , 2020, 21, 3700-3711.	1.9	10
93	Life expectancy of people who are dependent on opioids: A cohort study in New South Wales, Australia. <i>Journal of Psychiatric Research</i> , 2020, 130, 435-440.	3.1	15
94	Risk of discharge against medical advice among hospital inpatients with a history of opioid agonist therapy in New South Wales, Australia: A cohort study and nested crossover-cohort analysis. <i>Drug and Alcohol Dependence</i> , 2020, 217, 108343.	3.2	5
95	Generational trends in US opioid-overdose deaths. <i>Nature Medicine</i> , 2020, 26, 651-652.	30.7	8
96	Characteristics of gay and bisexual men who rarely use HIV risk reduction strategies during condomless anal intercourse: Results from the FLUX national online cohort study. <i>PLoS ONE</i> , 2020, 15, e0233922.	2.5	7
97	The association between parental supply of alcohol and supply from other sources to young people: a prospective cohort. <i>Addiction</i> , 2020, 115, 2140-2147.	3.3	4
98	Prevalence and Characteristics Associated with Chronic Noncancer Pain in Suicide Decedents: A National Study. <i>Suicide and Life-Threatening Behavior</i> , 2020, 50, 778-791.	1.9	11
99	Rates, characteristics and manner of cannabis-related deaths in Australia 2000â€“2018. <i>Drug and Alcohol Dependence</i> , 2020, 212, 108028.	3.2	14
100	The overall effect of parental supply of alcohol across adolescence on alcoholâ€“related harms in early adulthoodâ€“a prospective cohort study. <i>Addiction</i> , 2020, 115, 1833-1843.	3.3	10
101	Socio-demographic and ecological factors associated with anti-HCV prevalence in people who inject drugs: A systematic review. <i>Drug and Alcohol Dependence</i> , 2020, 209, 107899.	3.2	3
102	Leveraging genome-wide data to investigate differences between opioid use vs. opioid dependence in 41,176 individuals from the Psychiatric Genomics Consortium. <i>Molecular Psychiatry</i> , 2020, 25, 1673-1687.	7.9	82
103	Genome-Wide Association Study of Opioid Cessation. <i>Journal of Clinical Medicine</i> , 2020, 9, 180.	2.4	17
104	Global systematic review and ecological analysis of HIV in people who inject drugs: National population sizes and factors associated with HIV prevalence. <i>International Journal of Drug Policy</i> , 2020, 77, 102656.	3.3	20
105	Cannabinoids for the treatment of mental disorders â€“ Author's reply. <i>Lancet Psychiatry</i> , 2020, 7, 127-128.	7.4	0
106	Association between Mental Disorders and Subsequent Medical Conditions. <i>New England Journal of Medicine</i> , 2020, 382, 1721-1731.	27.0	258
107	Global opioid agonist treatment: a review of clinical practices by country. <i>Addiction</i> , 2020, 115, 2243-2254.	3.3	50
108	Adolescent cannabis use disorders. , 2020, , 111-135.		2

#	ARTICLE	IF	CITATIONS
109	Burden of injury along the development spectrum: associations between the Socio-demographic Index and disability-adjusted life year estimates from the Global Burden of Disease Study 2017. <i>Injury Prevention</i> , 2020, 26, i12-i26.	2.4	44
110	Societal issues and policy implications related to the use of cannabinoids, cannabis, and cannabis-based medicines for pain management. <i>Pain</i> , 2020, Publish Ahead of Print, S110-S116.	4.2	10
111	Self-harm in primary school-aged children: Prospective cohort study. <i>PLoS ONE</i> , 2020, 15, e0242802.	2.5	14
112	The Mortality After Release from Incarceration Consortium (MARIC): Protocol for a multi-national, individual participant data meta-analysis. <i>International Journal of Population Data Science</i> , 2020, 5, 1145.	0.1	9
113	Concordance between the diagnostic guidelines for alcohol and cannabis use disorders in the draft ICD-11 and other classification systems: analysis of data from the WHO's World Mental Health Surveys. <i>Addiction</i> , 2019, 114, 534-552.	3.3	36
114	Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. <i>Addiction</i> , 2019, 114, 150-166.	3.3	178
115	Concerns and Help-Seeking Among Patients Using Opioids for Management of Chronic Noncancer Pain. <i>Pain Medicine</i> , 2019, 20, 758-769.	1.9	9
116	Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. <i>Molecular Psychiatry</i> , 2019, 24, 1868-1883.	7.9	215
117	Post-marketing studies of pharmaceutical opioid abuse-deterrent formulations: a framework for research design and reporting. <i>Addiction</i> , 2019, 114, 389-399.	3.3	11
118	Estimating Centre for Disease Control and Prevention-defined overdose risk in people prescribed opioids for chronic non-cancer pain: implications for take-home naloxone provision. <i>Internal Medicine Journal</i> , 2019, 49, 1054-1055.	0.8	10
119	Modelling the potential prevention benefits of a treat-all hepatitis C treatment strategy at global, regional and country levels: A modelling study. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1388-1403.	2.0	11
120	The prevalence of non-fatal overdose among people who inject drugs: A multi-stage systematic review and meta-analysis. <i>International Journal of Drug Policy</i> , 2019, 73, 172-184.	3.3	67
121	Take-Home Naloxone for the Emergency Interim Management of Opioid Overdose: The Public Health Application of an Emergency Medicine. <i>Drugs</i> , 2019, 79, 1395-1418.	10.9	67
122	The epidemiology of drug use disorders cross-nationally: Findings from the WHO's World Mental Health Surveys. <i>International Journal of Drug Policy</i> , 2019, 71, 103-112.	3.3	45
123	Public health implications of legalising the production and sale of cannabis for medicinal and recreational use. <i>Lancet, The</i> , 2019, 394, 1580-1590.	13.7	224
124	Global patterns of opioid use and dependence: harms to populations, interventions, and future action. <i>Lancet, The</i> , 2019, 394, 1560-1579.	13.7	404
125	Responding to global stimulant use: challenges and opportunities. <i>Lancet, The</i> , 2019, 394, 1652-1667.	13.7	169
126	New psychoactive substances: challenges for drug surveillance, control, and public health responses. <i>Lancet, The</i> , 2019, 394, 1668-1684.	13.7	195

#	ARTICLE	IF	CITATIONS
127	Strategies to reduce drug-related harm: responding to the evidence base. <i>Lancet, The</i> , 2019, 394, 1490-1493.	13.7	15
128	Characteristics and circumstances of heroin and pharmaceutical opioid overdose deaths: Comparison across opioids. <i>Drug and Alcohol Dependence</i> , 2019, 205, 107533.	3.2	23
129	Mental health outcomes associated with the use of amphetamines: A systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2019, 16, 81-97.	7.1	91
130	Reductions in emergency department presentations associated with opioid agonist treatment vary by geographic location: A retrospective study in New South Wales, Australia. <i>Drug and Alcohol Review</i> , 2019, 38, 690-698.	2.1	7
131	Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. <i>Lancet Psychiatry</i> , 2019, 6, 995-1010.	7.4	306
132	Global, regional, and national incidence, prevalence, and mortality of HIV, 1980â€“2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. <i>Lancet HIV</i> , 2019, 6, e831-e859.	4.7	341
133	Parental supply of alcohol as a predictor of adolescent alcohol consumption patterns: A prospective cohort. <i>Drug and Alcohol Dependence</i> , 2019, 204, 107529.	3.2	14
134	The effect of entry and retention in opioid agonist treatment on contact with the criminal justice system among opioid-dependent people: a retrospective cohort study. <i>Lancet Public Health</i> , 2019, 4, e334-e342.	10.0	29
135	Prevalence of HIV, HCV and HBV infection and sociodemographic characteristics of people who inject drugs in China: A systematic review and meta-analysis. <i>International Journal of Drug Policy</i> , 2019, 70, 87-93.	3.3	16
136	Mortality among people with regular or problematic use of amphetamines: a systematic review and meta-analysis. <i>Addiction</i> , 2019, 114, 1738-1750.	3.3	32
137	Alcohol Use Disorders in ICD-11: Past, Present, and Future. <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 1617-1631.	2.4	83
138	Alcohol and parenthood: An integrative analysis of the effects of transition to parenthood in three Australasian cohorts. <i>Drug and Alcohol Dependence</i> , 2019, 197, 326-334.	3.2	28
139	The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 435-444.	8.1	145
140	Cross-national patterns of substance use disorder treatment and associations with mental disorder comorbidity in the WHO World Mental Health Surveys. <i>Addiction</i> , 2019, 114, 1446-1459.	3.3	27
141	Effectiveness and framing of pharmaceutical opioid abuse-deterrent formulations. <i>Addiction</i> , 2019, 114, 404-405.	3.3	2
142	Does adolescent heavier alcohol use predict young adult aggression and delinquency? Parallel analyses from four Australasian cohort studies. <i>Aggressive Behavior</i> , 2019, 45, 427-436.	2.4	11
143	Association of Cohort and Individual Substance Use With Risk of Transitioning to Drug Use, Drug Use Disorder, and Remission From Disorder. <i>JAMA Psychiatry</i> , 2019, 76, 708.	11.0	27
144	Antidepressant Use Among People Prescribed Opioids for Chronic Noncancer Pain. <i>Pain Medicine</i> , 2019, 20, 2450-2458.	1.9	12

#	ARTICLE	IF	CITATIONS
145	Regulatory and other responses to the pharmaceutical opioid problem. Medical Journal of Australia, 2019, 210, 6.	1.7	36
146	A Global Meta-analysis of the Prevalence of HIV, Hepatitis C Virus, and Hepatitis B Virus Among People Who Inject Drugsâ€”Do Gender-Based Differences Vary by Country-Level Indicators?. Journal of Infectious Diseases, 2019, 220, 78-90.	4.0	29
147	Trends in methamphetamine and opioid use among clients of needleâ€”syringe programs in Queensland, Australia: 2007â€”2015. Drug and Alcohol Review, 2019, 38, 159-168.	2.1	0
148	Protocol for the Data-Linkage Alcohol Cohort Study (DACS): investigating mortality, morbidity and offending among people with an alcohol-related problem using linked administrative data. BMJ Open, 2019, 9, e030605.	1.9	11
149	HIV Pre-exposure Prophylaxis (PrEP) Uptake Among Gay and Bisexual Men in Australia and Factors Associated With the Nonuse of PrEP Among Eligible Men: Results From a Prospective Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, e73-e84.	2.1	51
150	Cannabinoids, cannabis, and cannabis-based medicine for pain management: a protocol for an overview of systematic reviews and a systematic review of randomised controlled trials. Pain Reports, 2019, 4, e741.	2.7	18
151	Increases in controlledâ€”release oxycodone utilisation following the subsidy of oxycodone with naloxone formulations: An Australian populationâ€”based study. Pharmacoepidemiology and Drug Safety, 2019, 28, 97-105.	1.9	6
152	Longitudinal patterns of amphetamine use from adolescence to adulthood: A latent class analysis of a 20-year prospective study of Australians. Drug and Alcohol Dependence, 2019, 194, 121-127.	3.2	7
153	A population-based study of transdermal fentanyl initiation in Australian clinical practice. European Journal of Clinical Pharmacology, 2019, 75, 401-408.	1.9	8
154	Exploring Comorbidity Within Mental Disorders Among a Danish National Population. JAMA Psychiatry, 2019, 76, 259.	11.0	374
155	Persistence and Subtype Stability of ADHD Among Substance Use Disorder Treatment Seekers. Journal of Attention Disorders, 2019, 23, 1438-1453.	2.6	34
156	Epidemiology of Substance Use Internationally. Advances in Prevention Science, 2019, , 19-36.	0.3	4
157	The impact of cohort substance use upon likelihood of transitioning through stages of alcohol and cannabis use and use disorder: Findings from the Australian National Survey on Mental Health and Wellbeing. Drug and Alcohol Review, 2018, 37, 546-556.	2.1	13
158	Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 741-753.	1.9	138
159	Physical appearance concerns are uniquely associated with the severity of steroid dependence and depression in anabolicâ€”androgenic steroid users. Drug and Alcohol Review, 2018, 37, 664-670.	2.1	27
160	Psychotic experiences and general medical conditions: a cross-national analysis based on 28 002 respondents from 16 countries in the WHO World Mental Health Surveys. Psychological Medicine, 2018, 48, 2730-2739.	4.5	27
161	Relationship between the duration of methamphetamine use and psychotic symptoms: A two-year prospective cohort study. Drug and Alcohol Dependence, 2018, 187, 363-369.	3.2	33
162	Familial alcohol supply, adolescent drinking and early alcohol onset in 45 low and middle income countries. Addictive Behaviors, 2018, 84, 178-185.	3.0	11

#	ARTICLE	IF	CITATIONS
163	The State of US Health, 1990-2016. JAMA - Journal of the American Medical Association, 2018, 319, 1444.	7.4	1,042
164	Association of parental supply of alcohol with adolescent drinking, alcohol-related harms, and alcohol use disorder symptoms: a prospective cohort study. Lancet Public Health, The, 2018, 3, e64-e71.	10.0	61
165	Systematic review and meta-analysis of cannabinoids in palliative medicine. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 220-234.	7.3	106
166	Mental health, drug use and sexual risk behavior among gay and bisexual men. International Journal of Drug Policy, 2018, 55, 169-179.	3.3	78
167	The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews. Current Neurology and Neuroscience Reports, 2018, 18, 8.	4.2	116
168	Longitudinal injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting: The HITS-p study. International Journal of Drug Policy, 2018, 54, 18-25.	3.3	46
169	The relationship between methamphetamine use and heterosexual behaviour: evidence from a prospective longitudinal study. Addiction, 2018, 113, 1276-1285.	3.3	36
170	The associations between psychotic experiences and substance use and substance use disorders: findings from the World Health Organization World Mental Health surveys. Addiction, 2018, 113, 924-934.	3.3	56
171	Trends in opioid utilisation in Australia, 2006-2015: Insights from multiple metrics. Pharmacoepidemiology and Drug Safety, 2018, 27, 504-512.	1.9	36
172	The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study. Lancet Psychiatry, the, 2018, 5, 155-166.	7.4	28
173	Person-level changes in oxycodone use after the introduction of a tamper-resistant formulation in Australia. Cmaj, 2018, 190, E355-E362.	2.0	9
174	Opioid use and harms associated with a sustained-release tapentadol formulation: a postmarketing study protocol. BMJ Open, 2018, 8, e020006.	1.9	3
175	Accurate identification of opioid overdose deaths using coronial data. Forensic Science International, 2018, 287, 40-46.	2.2	13
176	A polymorphism in the OPRM1 3'-untranslated region is associated with methadone efficacy in treating opioid dependence. Pharmacogenomics Journal, 2018, 18, 173-179.	2.0	23
177	Knowledge of Opioid Overdose and Attitudes to Supply of Take-Home Naloxone Among People with Chronic Noncancer Pain Prescribed Opioids. Pain Medicine, 2018, 19, 533-540.	1.9	32
178	Health service utilisation attributable to methamphetamine use in Australia: Patterns, predictors and national impact. Drug and Alcohol Review, 2018, 37, 196-204.	2.1	60
179	A nationwide study of the extent and factors associated with fentanyl use in Australia. Research in Social and Administrative Pharmacy, 2018, 14, 303-308.	3.0	7
180	Prescription Opioid Access Patterns and Factors Associated with Increasing Number of Prescribers, Pharmacies, and Dispensings: An Observational Study Using Pharmaceutical Claims. Pain Medicine, 2018, 19, 1170-1183.	1.9	6

#	ARTICLE	IF	CITATIONS
181	To what extent do data from pharmaceutical claims underâ€estimate opioid analgesic utilisation in Australia?. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 550-555.	1.9	35
182	Pharmaceutical opioid use and harm in Australia: The need for proactive and preventative responses. <i>Drug and Alcohol Review</i> , 2018, 37, S203-S205.	2.1	32
183	Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and metaâ€analysis. <i>Addiction</i> , 2018, 113, 545-563.	3.3	242
184	Health and wellbeing of Indigenous adolescents in Australia: a systematic synthesis of population data. <i>Lancet, The</i> , 2018, 391, 766-782.	13.7	100
185	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980â€2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1736-1788.	13.7	4,989
186	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990â€2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1923-1994.	13.7	3,269
187	Population and fertility by age and sex for 195 countries and territories, 1950â€2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1995-2051.	13.7	294
188	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990â€2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1789-1858.	13.7	8,569
189	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990â€2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1859-1922.	13.7	2,123
190	Transancestral GWAS of alcohol dependence reveals common genetic underpinnings with psychiatric disorders. <i>Nature Neuroscience</i> , 2018, 21, 1656-1669.	14.8	490
191	Combating escalating harms associated with pharmaceutical opioid use in Australia: the POPPY II study protocol. <i>BMJ Open</i> , 2018, 8, e025840.	1.9	17
192	Understanding an emerging treatment population: Protocol for and baseline characteristics of a prospective cohort of people receiving treatment for pharmaceutical opioid dependence. <i>Drug and Alcohol Review</i> , 2018, 37, 887-896.	2.1	5
193	Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) Study. <i>BMJ Open</i> , 2018, 8, e025204.	1.9	31
194	Current Opioid Access, Use, and Problems in Australasian Jurisdictions. <i>Current Addiction Reports</i> , 2018, 5, 464-472.	3.4	12
195	The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990â€2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Psychiatry,the</i> , 2018, 5, 987-1012.	7.4	885
196	Cannabis use and non-cancer chronic pain â€ Authors' reply. <i>Lancet Public Health, The</i> , 2018, 3, e469.	10.0	1
197	The association between psychotic experiences and health-related quality of life: a cross-national analysis based on World Mental Health Surveys. <i>Schizophrenia Research</i> , 2018, 201, 46-53.	2.0	20
198	Alcohol use disorder and associated physical health complications and treatment amongst individuals with and without opioid dependence: A case-control study. <i>Drug and Alcohol Dependence</i> , 2018, 188, 304-310.	3.2	4

#	ARTICLE	IF	CITATIONS
199	Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. <i>Pain</i> , 2018, 159, 1932-1954.	4.2	321
200	Age-related prevalence and twelve-month incidence of illicit drug use in a cohort of Australian gay and bisexual men: Results from the Flux Study. <i>Drug and Alcohol Dependence</i> , 2018, 188, 175-179.	3.2	5
201	Predictors of transitions across stages of heroin use and dependence prior to treatment-seeking among people in treatment for opioid dependence. <i>Drug and Alcohol Dependence</i> , 2018, 191, 145-151.	3.2	18
202	Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. <i>Lancet Public Health</i> , The, 2018, 3, e341-e350.	10.0	172
203	Intensive sex partying with gamma-hydroxybutyrate: factors associated with using gamma-hydroxybutyrate for chemsex among Australian gay and bisexual men – results from the Flux Study. <i>Sexual Health</i> , 2018, 15, 123.	0.9	40
204	Amphetamine use in the fourth decade of life: Social profiles from a population-based Australian cohort. <i>Drug and Alcohol Review</i> , 2018, 37, 743-751.	2.1	4
205	Adverse adult consequences of different alcohol use patterns in adolescence: an integrative analysis of data to age 30 years from four Australasian cohorts. <i>Addiction</i> , 2018, 113, 1811-1825.	3.3	43
206	Alcohol Use Disorders in the Draft ICD-11, and How They Compare with DSM-5. <i>Current Addiction Reports</i> , 2018, 5, 257-264.	3.4	17
207	Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. <i>Addiction</i> , 2018, 113, 1905-1926.	3.3	685
208	Mortality trends among people with hepatitis B and C: a population-based linkage study, 1993-2012. <i>BMC Infectious Diseases</i> , 2018, 18, 215.	2.9	22
209	Competing global statistics on prevalence of injecting drug use: why does it matter and what can be done?. <i>Addiction</i> , 2018, 113, 1768-1774.	3.3	11
210	Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet</i> , The, 2018, 392, 1015-1035.	13.7	2,005
211	Meeting Sexual Partners Through Internet Sites and Smartphone Apps in Australia: National Representative Study. <i>Journal of Medical Internet Research</i> , 2018, 20, e10683.	4.3	27
212	Cohort Profile: <i>Ten to Men</i> (the Australian Longitudinal Study on Male Health). <i>International Journal of Epidemiology</i> , 2017, 46, dyw055.	1.9	30
213	Opioid agonist doses for oxycodone and morphine dependence: Findings from a retrospective case series. <i>Drug and Alcohol Review</i> , 2017, 36, 311-316.	2.1	3
214	Crystalline methamphetamine use and methamphetamine-related harms in Australia. <i>Drug and Alcohol Review</i> , 2017, 36, 160-170.	2.1	126
215	Defined daily doses (DDD) do not accurately reflect opioid doses used in contemporary chronic pain treatment. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 587-591.	1.9	39
216	A systematic review of injecting-related injury and disease among people who inject drugs. <i>Drug and Alcohol Dependence</i> , 2017, 171, 39-49.	3.2	163

#	ARTICLE	IF	CITATIONS
217	Following Lives Undergoing Change (Flux) study: Implementation and baseline prevalence of drug use in an online cohort study of gay and bisexual men in Australia. <i>International Journal of Drug Policy</i> , 2017, 41, 41-50.	3.3	50
218	Substance dependence among those without symptoms of substance abuse in the World Mental Health Survey. <i>International Journal of Methods in Psychiatric Research</i> , 2017, 26, .	2.1	13
219	Parental supply of alcohol and alcohol consumption in adolescence: prospective cohort study. <i>Psychological Medicine</i> , 2017, 47, 267-278.	4.5	34
220	A mapping review of take-home naloxone for people released from correctional settings. <i>International Journal of Drug Policy</i> , 2017, 46, 7-16.	3.3	20
221	New developments and opportunities for preventing hepatitis C virus (HCV) among people who use and inject drugs-announcing an <i>Addiction</i> series. <i>Addiction</i> , 2017, 112, 1126-1127.	3.3	2
222	Excessive gambling and gaming: addictive disorders?. <i>Lancet Psychiatry</i> , the, 2017, 4, 433-435.	7.4	9
223	Trends in new psychoactive substances from surface and "dark"-net monitoring. <i>Lancet Psychiatry</i> , the, 2017, 4, 16-18.	7.4	15
224	Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. <i>The Lancet Global Health</i> , 2017, 5, e1192-e1207.	6.3	1,020
225	Estimating treatment coverage for people with substance use disorders: an analysis of data from the World Mental Health Surveys. <i>World Psychiatry</i> , 2017, 16, 299-307.	10.4	160
226	Trends in heroin and pharmaceutical opioid overdose deaths in Australia. <i>Drug and Alcohol Dependence</i> , 2017, 179, 291-298.	3.2	142
227	Association Between Psychotic Experiences and Subsequent Suicidal Thoughts and Behaviors. <i>JAMA Psychiatry</i> , 2017, 74, 1136.	11.0	75
228	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet</i> , The, 2017, 390, 1084-1150.	13.7	573
229	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet</i> , The, 2017, 390, 1260-1344.	13.7	1,589
230	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet</i> , The, 2017, 390, 1151-1210.	13.7	3,565
231	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet</i> , The, 2017, 390, 1211-1259.	13.7	5,578
232	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet</i> , The, 2017, 390, 1345-1422.	13.7	1,879
233	Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. <i>The Cochrane Library</i> , 2017, 2017, CD012021.	2.8	158
234	Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. <i>Lancet</i> , The, 2017, 390, 1423-1459.	13.7	284

#	ARTICLE	IF	CITATIONS
235	Escalating patterns of emergency health care prior to first admission with amphetamine psychosis: A window of opportunity?. Drug and Alcohol Dependence, 2017, 180, 171-177.	3.2	11
236	Estimating the number of adults with severe and persistent mental illness who have complex, multi-agency needs. Australian and New Zealand Journal of Psychiatry, 2017, 51, 799-809.	2.3	15
237	Trauma and PTSD in the WHO World Mental Health Surveys. H�tgre Utbildning, 2017, 8, 1353383.	3.0	801
238	Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. The Lancet Global Health, 2017, 5, e1208-e1220.	6.3	334
239	Peer Victimization and Academic Performance in Primary School Children. Academic Pediatrics, 2017, 17, 830-836.	2.0	32
240	Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. International Journal of Drug Policy, 2017, 47, 51-60.	3.3	54
241	The descriptive epidemiology of DSM-IV Adult ADHD in the World Health Organization World Mental Health Surveys. ADHD Attention Deficit and Hyperactivity Disorders, 2017, 9, 47-65.	1.7	507
242	Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ: British Medical Journal, 2017, 357, j1550.	2.3	1,076
243	Illicit Drugs: Patterns of Use, Dependence, and Contribution to Disease Burden in Developed Countries. , 2017, , 134-145.		2
244	The Burden of Mental Disorders in the Eastern Mediterranean Region, 1990-2013. PLoS ONE, 2017, 12, e0169575.	2.5	102
245	Estimating the number of people who inject drugs in Australia. BMC Public Health, 2017, 17, 757.	2.9	38
246	Geographic Variation in Health Service Use and Perceived Access Barriers for Australian Adults with Chronic Non-Cancer Pain Receiving Opioid Therapy. Pain Medicine, 2016, 17, 2003-2016.	1.9	10
247	Estimating the number of regular and dependent methamphetamine users in Australia, 2002��2014. Medical Journal of Australia, 2016, 205, 426-426.	1.7	1
248	Estimating the number of regular and dependent methamphetamine users in Australia, 2002��2014. Medical Journal of Australia, 2016, 204, 153-153.	1.7	78
249	Initiation of strong prescription opioids in Australia: cohort characteristics and factors associated with the type of opioid initiated. British Journal of Clinical Pharmacology, 2016, 82, 1123-1133.	2.4	18
250	Sleep Quality Among People Living With Chronic Noncancer Pain. Clinical Journal of Pain, 2016, 32, 380-387.	1.9	10
251	Defining problematic pharmaceutical opioid use among people prescribed opioids for chronic noncancer pain: do different measures identify the same patients?. Pain, 2016, 157, 1489-1498.	4.2	43
252	The influence of personality disorder on the future mental health and social adjustment of young adults: a population-based, longitudinal cohort study. Lancet Psychiatry,the, 2016, 3, 636-645.	7.4	82

#	ARTICLE	IF	CITATIONS
253	The extent and correlates of community-based pharmaceutical opioid utilisation in Australia. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 521-538.	1.9	63
254	A synthesis of oral morphine equivalents (OME) for opioid utilisation studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 733-737.	1.9	322
255	A cross-sectional study of correlates of imprisonment in opioid-dependent men and women in New South Wales, Australia. <i>Drug and Alcohol Review</i> , 2016, 35, 686-692.	2.1	7
256	Is sexual content in new media linked to sexual risk behaviour in young people? A systematic review and meta-analysis. <i>Sexual Health</i> , 2016, 13, 501.	0.9	33
257	Adolescent Predictors of a Typology of DSM-5 Alcohol Use Disorder Symptoms in Young Adults Derived by Latent Class Analysis Using Data From an Australian Cohort Study. <i>Journal of Studies on Alcohol and Drugs</i> , 2016, 77, 757-765.	1.0	9
258	Preventing depression and anxiety in young people: a review of the joint efficacy of universal, selective and indicated prevention. <i>Psychological Medicine</i> , 2016, 46, 11-26.	4.5	232
259	The association between childhood maltreatment, psychopathology, and adult sexual victimization in men and women: results from three independent samples. <i>Psychological Medicine</i> , 2016, 46, 563-573.	4.5	37
260	Excess mortality from mental, neurological and substance use disorders in the Global Burden of Disease Study 2010 – CORRIGENDUM. <i>Epidemiology and Psychiatric Sciences</i> , 2016, 25, 91-92.	3.9	1
261	Development of a brief tool for monitoring aberrant behaviours among patients receiving long-term opioid therapy: The Opioid-Related Behaviours In Treatment (ORBIT) scale. <i>Drug and Alcohol Dependence</i> , 2016, 159, 42-52.	3.2	27
262	Global burden of diseases, injuries, and risk factors for young people's health during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2016, 387, 2383-2401.	13.7	710
263	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1603-1658.	13.7	1,612
264	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1459-1544.	13.7	4,934
265	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1545-1602.	13.7	5,298
266	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1659-1724.	13.7	4,203
267	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1725-1774.	13.7	571
268	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1813-1850.	13.7	413
269	Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. <i>Lancet Infectious Diseases, The</i> , 2016, 16, 1385-1398.	9.1	223
270	Same-day use of opioids and other central nervous system depressants amongst people who tamper with pharmaceutical opioids: A retrospective 7-day diary study. <i>Drug and Alcohol Dependence</i> , 2016, 166, 125-133.	3.2	11

#	ARTICLE	IF	CITATIONS
271	The variance shared across forms of childhood trauma is strongly associated with liability for psychiatric and substance use disorders. <i>Brain and Behavior</i> , 2016, 6, e00432.	2.2	20
272	Response to Bird <i>et al</i>.: The importance of post-release engagement in treatment in estimating impacts on post-release deaths. <i>Addiction</i> , 2016, 111, 560-561.	3.3	0
273	Commentary on Cousins et al. (2016): Accumulating evidence on risk of mortality on and off opioid substitution treatment. <i>Addiction</i> , 2016, 111, 83-84.	3.3	1
274	Diversion and injection of buprenorphine-naloxone film two years post-introduction in Australia. <i>Drug and Alcohol Review</i> , 2016, 35, 83-91.	2.1	15
275	Concordance of ICD-11 and DSM-5 definitions of alcohol and cannabis use disorders: a population survey. <i>Lancet Psychiatry</i> , 2016, 3, 673-684.	7.4	47
276	The prevalence and burden of bipolar disorder: findings from the Global Burden of Disease Study 2013. <i>Bipolar Disorders</i> , 2016, 18, 440-450.	1.9	426
277	A systematic review and meta-analysis of racial and ethnic disparities in hepatitis C antibody prevalence in United States correctional populations. <i>Annals of Epidemiology</i> , 2016, 26, 570-578.e2.	1.9	8
278	Community pharmacist knowledge, attitudes and confidence regarding naloxone for overdose reversal. <i>Addiction</i> , 2016, 111, 2177-2186.	3.3	61
279	A Cross-National Examination of Differences in Classification of Lifetime Alcohol Use Disorder Between <sc>DSM</sc>â€‹<sc>IV</sc> and <sc>DSM</sc>â€‹<sc>5</sc>: Findings from the World Mental Health Survey. <i>Alcoholism: Clinical and Experimental Research</i> , 2016, 40, 1728-1736.	2.4	35
280	Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980â€‹2015: the Global Burden of Disease Study 2015. <i>Lancet HIV</i> , 2016, 3, e361-e387.	4.7	461
281	Age-related differences in patterns of criminal activity among a large sample of polydrug injectors in Australia. <i>Journal of Substance Use</i> , 2016, 21, 48-56.	0.7	12
282	The Australian longitudinal study on male health-methods. <i>BMC Public Health</i> , 2016, 16, 1030.	2.9	37
283	Health service utilisation by people living with chronic non-cancer pain: findings from the Pain and Opioids IN Treatment (POINT) study. <i>Australian Health Review</i> , 2016, 40, 490.	1.1	8
284	Opioid agonist treatment for pharmaceutical opioid dependent people. <i>The Cochrane Library</i> , 2016, , CD011117.	2.8	148
285	An ecological study of the extent and factors associated with the use of prescription and over-the-counter codeine in Australia. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 469-494.	1.9	37
286	Prevalence and Correlates of Suicidal Thoughts and Suicide Attempts in People Prescribed Pharmaceutical Opioids for Chronic Pain. <i>Clinical Journal of Pain</i> , 2016, 32, 292-301.	1.9	39
287	Global Burden Of Disease Studies: Implications For Mental And Substance Use Disorders. <i>Health Affairs</i> , 2016, 35, 1114-1120.	5.2	84
288	Pain, alcohol use disorders and risky patterns of drinking among people with chronic non-cancer pain receiving long-term opioid therapy. <i>Drug and Alcohol Dependence</i> , 2016, 162, 79-87.	3.2	40

#	ARTICLE	IF	CITATIONS
289	Global and National Burden of Diseases and Injuries Among Children and Adolescents Between 1990 and 2013. JAMA Pediatrics, 2016, 170, 267.	6.2	479
290	Treating codeine dependence with buprenorphine: Dose requirements and induction outcomes from a retrospective case series in <scp>N</scp>ew <scp>S</scp>outh <scp>W</scp>ales, <scp>A</scp>ustralia. Drug and Alcohol Review, 2016, 35, 70-75.	2.1	7
291	The extramedical use and diversion of opioid substitution medications and other medications in prison settings in <scp>A</scp>ustralia following the introduction of buprenorphineâ€ˆnaloxone film. Drug and Alcohol Review, 2016, 35, 76-82.	2.1	21
292	Prevention, early intervention, harm reduction, and treatment of substance use in young people. Lancet Psychiatry,the, 2016, 3, 280-296.	7.4	296
293	The increasing global health priority of substance use in young people. Lancet Psychiatry,the, 2016, 3, 251-264.	7.4	378
294	Why young people's substance use matters for global health. Lancet Psychiatry,the, 2016, 3, 265-279.	7.4	230
295	Sexual identity and prevalence of alcohol and other drug use among Australians in the general population. International Journal of Drug Policy, 2016, 28, 76-82.	3.3	104
296	The global burden of injury: incidence, mortality, disability-adjusted life years and time trends from the Global Burden of Disease study 2013. Injury Prevention, 2016, 22, 3-18.	2.4	898
297	Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts. Behavior Genetics, 2016, 46, 151-169.	2.1	98
298	Addressing the burden of mental, neurological, and substance use disorders: key messages from Disease Control Priorities, 3rd edition. Lancet, The, 2016, 387, 1672-1685.	13.7	586
299	Evidence of CNH3 involvement in opioid dependence. Molecular Psychiatry, 2016, 21, 608-614.	7.9	109
300	Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs. , 2016, 2016, .		38
301	Global Priorities for Addressing the Burden of Mental, Neurological, and Substance Use Disorders. , 2016, , 1-27.		23
302	Global Burden of Mental, Neurological, and Substance Use Disorders: An Analysis from the Global Burden of Disease Study 2010. , 2016, , 29-40.		16
303	Excess Mortality from Mental, Neurological, and Substance Use Disorders in the Global Burden of Disease Study 2010. , 2016, , 41-65.		24
304	Illicit Drug Dependence. , 2016, , 109-125.		10
305	A Typology of Predictive Risk Factors for Non-Adherent Medication-Related Behaviors among Chronic Non-Cancer Pain Patients Prescribed Opioids: A Cohort Study. Pain Physician, 2016, 19, E421-34.	0.4	1
306	The Global Burden of Mental, Neurological and Substance Use Disorders: An Analysis from the Global Burden of Disease Study 2010. PLoS ONE, 2015, 10, e0116820.	2.5	908

#	ARTICLE	IF	CITATIONS
307	Patterns of, and Factors Associated With, Illicit Pharmaceutical Opioid Analgesic Use in a Prospective Cohort of People Who Inject Drugs in Melbourne, Australia. <i>Substance Use and Misuse</i> , 2015, 50, 1650-1659.	1.4	4
308	Does the social context of early alcohol use affect risky drinking in adolescents? Prospective cohort study. <i>BMC Public Health</i> , 2015, 15, 1137.	2.9	17
309	Examining the quality of name code record linkage: what is the impact on death and cancer risk estimates? A validation study. <i>Australian and New Zealand Journal of Public Health</i> , 2015, 39, 141-147.	1.8	9
310	The introduction of buprenorphine-naloxone film in opioid substitution therapy in Australia: Uptake and issues arising from changing buprenorphine formulations. <i>Drug and Alcohol Review</i> , 2015, 34, 603-610.	2.1	8
311	Injecting buprenorphine-naloxone film: Findings from an explorative qualitative study. <i>Drug and Alcohol Review</i> , 2015, 34, 623-629.	2.1	6
312	The use of paracetamol (acetaminophen) among a community sample of people with chronic non-cancer pain prescribed opioids. <i>International Journal of Clinical Practice</i> , 2015, 69, 1366-1376.	1.7	7
313	Potential bias due to outcome-related loss to follow-up in cohort studies on incidence of drug injection: systematic review and meta-analysis. <i>Addiction</i> , 2015, 110, 1247-1257.	3.3	11
314	A cost-effectiveness analysis of opioid substitution therapy upon prison release in reducing mortality among people with a history of opioid dependence. <i>Addiction</i> , 2015, 110, 1975-1984.	3.3	29
315	Jurisdictional differences in opioid use, other licit and illicit drug use, and harms associated with substance use among people who tamper with pharmaceutical opioids. <i>Drug and Alcohol Review</i> , 2015, 34, 611-622.	2.1	10
316	A typology of people who tamper with pharmaceutical opioids: responses to introduction of a tamper-resistant formulation of controlled-release oxycodone. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 1321-1333.	1.9	4
317	Global Epidemiology of HIV Among Women and Girls Who Use or Inject Drugs. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, S100-S109.	2.1	46
318	Trends and characteristics of accidental and intentional codeine overdose deaths in Australia. <i>Medical Journal of Australia</i> , 2015, 203, 299-299.	1.7	63
319	A heavy burden on young minds: the global burden of mental and substance use disorders in children and youth. <i>Psychological Medicine</i> , 2015, 45, 1551-1563.	4.5	444
320	Associations of borderline personality with pain, problems with medications and suicidality in a community sample of chronic non-cancer pain patients prescribed opioids for pain. <i>General Hospital Psychiatry</i> , 2015, 37, 434-440.	2.4	24
321	Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2015, 386, 743-800.	13.7	4,951
322	Pharmaceutical Opioid Use and Dependence among People Living with Chronic Pain: Associations Observed within the Pain and Opioids in Treatment (POINT) Cohort. <i>Pain Medicine</i> , 2015, 16, 1745-1758.	1.9	78
323	Benzodiazepine Use among Chronic Pain Patients Prescribed Opioids: Associations with Pain, Physical and Mental Health, and Health Service Utilization. <i>Pain Medicine</i> , 2015, 16, 356-366.	1.9	102
324	The POPPY Research Programme protocol: investigating opioid utilisation, costs and patterns of extramedical use in Australia. <i>BMJ Open</i> , 2015, 5, e007030-e007030.	1.9	9

#	ARTICLE	IF	CITATIONS
325	Agreement between definitions of pharmaceutical opioid use disorders and dependence in people taking opioids for chronic non-cancer pain (POINT): a cohort study. <i>Lancet Psychiatry</i> , 2015, 2, 314-322.	7.4	55
326	Incidence and predictors of non-fatal drug overdose after release from prison among people who inject drugs in Queensland, Australia. <i>Drug and Alcohol Dependence</i> , 2015, 153, 43-49.	3.2	54
327	How do drug market changes affect characteristics of injecting initiation and subsequent patterns of drug use? Findings from a cohort of regular heroin and methamphetamine injectors in Melbourne, Australia. <i>International Journal of Drug Policy</i> , 2015, 26, 43-50.	3.3	22
328	Experience of adjunctive cannabis use for chronic non-cancer pain: Findings from the Pain and Opioids IN Treatment (POINT) study. <i>Drug and Alcohol Dependence</i> , 2015, 147, 144-150.	3.2	97
329	Opioid substitution therapy is associated with increased detection of hepatitis C virus infection: A 15-year observational cohort study. <i>Drug and Alcohol Dependence</i> , 2015, 148, 213-216.	3.2	11
330	Symptom screening scales for detecting major depressive disorder in children and adolescents: A systematic review and meta-analysis of reliability, validity and diagnostic utility. <i>Journal of Affective Disorders</i> , 2015, 174, 447-463.	4.1	182
331	Sexual identity, same-sex partners and risk behaviour among a community-based sample of young people in Australia. <i>International Journal of Drug Policy</i> , 2015, 26, 153-161.	3.3	11
332	Mortality among older adults with opioid use disorders in the Veteran's Health Administration, 2000-2011. <i>Drug and Alcohol Dependence</i> , 2015, 147, 32-37.	3.2	52
333	The prevalence and correlates of chronic pain and suicidality in a nationally representative sample. <i>Australian and New Zealand Journal of Psychiatry</i> , 2015, 49, 803-811.	2.3	69
334	Methods and predictors of tampering with a tamper-resistant controlled-release oxycodone formulation. <i>International Journal of Drug Policy</i> , 2015, 26, 1265-1272.	3.3	13
335	Variation in mortality risk of people released from prison. <i>Lancet Psychiatry</i> , 2015, 2, 681.	7.4	3
336	The introduction of a potentially abuse deterrent oxycodone formulation: Early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study. <i>Drug and Alcohol Dependence</i> , 2015, 151, 56-67.	3.2	29
337	The impact of blood-borne viruses on cause-specific mortality among opioid dependent people: An Australian population-based cohort study. <i>Drug and Alcohol Dependence</i> , 2015, 152, 264-271.	3.2	15
338	Factors associated with the development of depression in chronic non-cancer pain patients following the onset of opioid treatment for pain. <i>Journal of Affective Disorders</i> , 2015, 184, 72-80.	4.1	30
339	Excess mortality from mental, neurological and substance use disorders in the Global Burden of Disease Study 2010. <i>Epidemiology and Psychiatric Sciences</i> , 2015, 24, 121-140.	3.9	96
340	How can data harmonisation benefit mental health research? An example of The Cannabis Cohorts Research Consortium. <i>Australian and New Zealand Journal of Psychiatry</i> , 2015, 49, 317-323.	2.3	20
341	Substance use in adulthood following adolescent self-harm: a population-based cohort study. <i>Acta Psychiatrica Scandinavica</i> , 2015, 131, 61-68.	4.5	56
342	Changes in non-opioid substitution treatment episodes for pharmaceutical opioids and heroin from 2002 to 2011. <i>Drug and Alcohol Dependence</i> , 2015, 149, 212-219.	3.2	40

#	ARTICLE	IF	CITATIONS
343	High potency cannabis. <i>BMJ, The</i> , 2015, 350, h1205-h1205.	6.0	39
344	Comorbid attention deficit hyperactivity disorder and substance use disorder complexity and chronicity in treatment-seeking adults. <i>Drug and Alcohol Review</i> , 2015, 34, 683-693.	2.1	47
345	The Pain and Opioids IN Treatment study. <i>Pain</i> , 2015, 156, 231-242.	4.2	104
346	Adolescent substance use and educational attainment: An integrative data analysis comparing cannabis and alcohol from three Australasian cohorts. <i>Drug and Alcohol Dependence</i> , 2015, 156, 90-96.	3.2	82
347	Editorial Commentary: The Impact of Opiate Substitution Therapy and Highly Active Antiretroviral Therapy on Mortality Risk Among People Who Inject Drugs. <i>Clinical Infectious Diseases</i> , 2015, 61, 1166-1168.	5.8	4
348	Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study. <i>Lancet Psychiatry, the</i> , 2015, 2, 901-908.	7.4	106
349	Defining populations and injecting parameters among people who inject drugs: Implications for the assessment of hepatitis C treatment programs. <i>International Journal of Drug Policy</i> , 2015, 26, 950-957.	3.3	42
350	Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Detection (NOMAD) study protocol. <i>Addiction</i> , 2015, 110, 226-237.	3.3	19
351	A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia. <i>Addiction</i> , 2015, 110, 646-655.	3.3	57
352	Substance use and risk of death in young offenders: A prospective data linkage study. <i>Drug and Alcohol Review</i> , 2015, 34, 46-50.	2.1	23
353	Excess mortality among opioid-using patients treated with oral naltrexone in Australia. <i>Drug and Alcohol Review</i> , 2015, 34, 90-96.	2.1	18
354	Comparing treatment-seeking codeine users and strong opioid users: Findings from a novel case series. <i>Drug and Alcohol Review</i> , 2015, 34, 304-311.	2.1	25
355	Associations between psychotic symptoms and substance use in young offenders. <i>Drug and Alcohol Review</i> , 2015, 34, 673-682.	2.1	21
356	Estimating service demand for respite care among informal carers of people with psychological disabilities in Australia. <i>Australian and New Zealand Journal of Public Health</i> , 2015, 39, 284-292.	1.8	15
357	Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. <i>Lancet, The</i> , 2015, 386, 2145-2191.	13.7	1,544
358	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2015, 386, 2287-2323.	13.7	2,184
359	Cis-Expression Quantitative Trait Loci Mapping Reveals Replicable Associations with Heroin Addiction in OPRM1. <i>Biological Psychiatry</i> , 2015, 78, 474-484.	1.3	64
360	Burden attributable to child maltreatment in Australia. <i>Child Abuse and Neglect</i> , 2015, 48, 208-220.	2.6	112

#	ARTICLE	IF	CITATIONS
361	The characteristics of a cohort who tamper with prescribed and diverted opioid medications. Journal of Substance Abuse Treatment, 2015, 58, 51-61.	2.8	20
362	Reducing extramedical use and harms of pharmaceutical opioids: the potential role of abuse-deterrent formulations. Lancet Psychiatry, 2015, 2, 957-959.	7.4	3
363	Global, regional, and national age- and sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 2015, 385, 117-171.	13.7	5,847
364	Monoacylglycerol lipase (MGLL) polymorphism rs604300 interacts with childhood adversity to predict cannabis dependence symptoms and amygdala habituation: Evidence from an endocannabinoid system-level analysis. Journal of Abnormal Psychology, 2015, 124, 860-877.	1.9	39
365	The Burden Attributable to Mental and Substance Use Disorders as Risk Factors for Suicide: Findings from the Global Burden of Disease Study 2010. PLoS ONE, 2014, 9, e91936.	2.5	335
366	Illicit Drugs. , 2014, , .		0
367	Offending, custody and opioid substitution therapy treatment utilisation among opioid-dependent people in contact with the criminal justice system: comparison of Indigenous and non-Indigenous Australians. BMC Public Health, 2014, 14, 920.	2.9	10
368	Opioid substitution therapy as a strategy to reduce deaths in prison: retrospective cohort study. BMJ Open, 2014, 4, e004666.	1.9	54
369	Reply. Hepatology, 2014, 59, 733-734.	7.3	1
370	Afghanistan has a sizeable problem with opioid use. The Lancet Global Health, 2014, 2, e557-e558.	6.3	3
371	Imprisonment of opioid-dependent people in New South Wales, Australia, 2000-2012: a retrospective linkage study. Australian and New Zealand Journal of Public Health, 2014, 38, 165-170.	1.8	10
372	PTSD risk associated with a functional DRD2 polymorphism in heroin-dependent cases and controls is limited to amphetamine-dependent individuals. Addiction Biology, 2014, 19, 700-707.	2.6	11
373	The Global Burden of Disease projects: What have we learned about illicit drug use and dependence and their contribution to the global burden of disease?. Drug and Alcohol Review, 2014, 33, 4-12.	2.1	75
374	Response to Hser et al. (2014): The necessity for more and better data on the global epidemiology of opioid dependence. Addiction, 2014, 109, 1335-1337.	3.3	3
375	Poor health and social outcomes for ex-prisoners with a history of mental disorder: a longitudinal study. Australian and New Zealand Journal of Public Health, 2014, 38, 424-429.	1.8	48
376	Diversion of prescribed opioids by people living with chronic pain: Results from an Australian community sample. Drug and Alcohol Review, 2014, 33, 27-32.	2.1	11
377	The impact of opioid substitution therapy on mortality post-release from prison: retrospective data linkage study. Addiction, 2014, 109, 1306-1317.	3.3	165
378	A comparative study of opioid substitution therapy utilisation among opioid-dependent men and women. Drug and Alcohol Review, 2014, 33, 499-505.	2.1	3

#	ARTICLE	IF	CITATIONS
379	Hepatitis C testing and status among opioid substitution treatment clients in New South Wales. Australian and New Zealand Journal of Public Health, 2014, 38, 160-164.	1.8	9
380	Factors associated with the timing and onset of cannabis use and cannabis use disorder: Results from the 2007 Australian National Survey of Mental Health and Wellbeing. Drug and Alcohol Review, 2014, 33, 555-564.	2.1	44
381	The global burden of mental and substance use disorders: changes in estimating burden between GBD1990 and GBD2010. Epidemiology and Psychiatric Sciences, 2014, 23, 239-249.	3.9	17
382	Pattern and characteristics of ecstasy and related drug (ERD) presentations at two hospital emergency departments, Melbourne, Australia, 2008-2010. Emergency Medicine Journal, 2014, 31, 317-322.	1.0	24
383	Commentary: Improving the mental health and substance use estimates in the Global Burden of Disease study: strengthening the evidence base for public policy. International Journal of Epidemiology, 2014, 43, 296-301.	1.9	10
384	Examining non-AIDS mortality among people who inject drugs. Aids, 2014, 28, S435-S444.	2.2	32
385	Causes of death in a cohort treated for opioid dependence between 1985 and 2005. Addiction, 2014, 109, 90-99.	3.3	92
386	Self-Harm in Young Offenders. Suicide and Life-Threatening Behavior, 2014, 44, 641-652.	1.9	22
387	Association of OPRD1 polymorphisms with heroin dependence in a large case-control series. Addiction Biology, 2014, 19, 111-121.	2.6	70
388	The prognosis of common mental disorders in adolescents: a 14-year prospective cohort study. Lancet, The, 2014, 383, 1404-1411.	13.7	379
389	The global epidemiology and burden of psychostimulant dependence: Findings from the Global Burden of Disease Study 2010. Drug and Alcohol Dependence, 2014, 137, 36-47.	3.2	126
390	The adverse health effects of chronic cannabis use. Drug Testing and Analysis, 2014, 6, 39-45.	2.6	288
391	The diversion and injection of a buprenorphine-naloxone soluble film formulation. Drug and Alcohol Dependence, 2014, 136, 21-27.	3.2	43
392	The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study. Addiction, 2014, 109, 1320-1333.	3.3	308
393	Psychiatric comorbidity in treatment-seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the IASP study. Addiction, 2014, 109, 262-272.	3.3	129
394	What has been achieved in HIV prevention, treatment and care for people who inject drugs, 2010-2012? A review of the six highest burden countries. International Journal of Drug Policy, 2014, 25, 53-60.	3.3	145
395	Alcohol abuse in developed and developing countries in the World Mental Health Surveys: Socially defined consequences or psychiatric disorder?. American Journal on Addictions, 2014, 23, 145-155.	1.4	15
396	A systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence. Drug and Alcohol Review, 2014, 33, 115-128.	2.1	41

#	ARTICLE	IF	CITATIONS
397	Effects of HIV Antiretroviral Therapy on Sexual and Injecting Risk-Taking Behavior: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2014, 59, 1483-1494.	5.8	33
398	Risk behaviours among substance use disorder treatment seekers with and without adult ADHD symptoms. <i>Drug and Alcohol Dependence</i> , 2014, 144, 70-77.	3.2	33
399	Young adult sequelae of adolescent cannabis use: an integrative analysis. <i>Lancet Psychiatry</i> , the, 2014, 1, 286-293.	7.4	354
400	Cocaine use and risk of stroke: A systematic review. <i>Drug and Alcohol Dependence</i> , 2014, 142, 1-13.	3.2	98
401	Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2014, 384, 1005-1070.	13.7	786
402	Cohort protocol paper: The Pain and Opioids In Treatment (POINT) study. <i>BMC Pharmacology & Toxicology</i> , 2014, 15, 17.	2.4	39
403	Variability in the prevalence of adult ADHD in treatment seeking substance use disorder patients: Results from an international multi-center study exploring DSM-IV and DSM-5 criteria. <i>Drug and Alcohol Dependence</i> , 2014, 134, 158-166.	3.2	150
404	Global, regional, and national levels and causes of maternal mortality during 1990â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2014, 384, 980-1004.	13.7	1,230
405	Complex Health Needs in the Youth Justice System: A Survey of Community-Based and Custodial Offenders. <i>Journal of Adolescent Health</i> , 2014, 54, 521-526.	2.5	40
406	Predictive validity of the AUDIT for hazardous alcohol consumption in recently released prisoners. <i>Drug and Alcohol Dependence</i> , 2014, 134, 322-329.	3.2	19
407	A latent class analysis of self-reported clinical indicators of psychosocial stability and adherence among opioid substitution therapy patients: Do stable patients receive more unsupervised doses?. <i>Drug and Alcohol Dependence</i> , 2014, 142, 46-55.	3.2	14
408	Effect of Intubation for Gammaâ€“hydroxybutyric Acid Overdose on Emergency Department Length of Stay and Hospital Admission. <i>Academic Emergency Medicine</i> , 2014, 21, 1226-1231.	1.8	19
409	Mental and Substance Use Disorders in Sub-Saharan Africa: Predictions of Epidemiological Changes and Mental Health Workforce Requirements for the Next 40 Years. <i>PLoS ONE</i> , 2014, 9, e110208.	2.5	102
410	Establishing the Melbourne injecting drug user cohort study (MIX): rationale, methods, and baseline and twelve-month follow-up results. <i>Harm Reduction Journal</i> , 2013, 10, 11.	3.2	82
411	Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2013, 382, 1575-1586.	13.7	4,651
412	Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2013, 382, 1564-1574.	13.7	668
413	Study protocol: the Childhood to Adolescence Transition Study (CATS). <i>BMC Pediatrics</i> , 2013, 13, 160.	1.7	61
414	Engagement with the criminal justice system among opioid-dependent people: a retrospective cohort study. <i>Addiction</i> , 2013, 108, 2152-2165.	3.3	20

#	ARTICLE	IF	CITATIONS
415	Correlates of pain in an in-treatment sample of opioid-dependent people. Drug and Alcohol Review, 2013, 32, 489-494.	2.1	8
416	A randomised controlled trial of sublingual buprenorphine-naloxone film versus tablets in the management of opioid dependence. Drug and Alcohol Dependence, 2013, 131, 119-126.	3.2	39
417	The relationship between age and risky injecting behaviours among a sample of Australian people who inject drugs. Drug and Alcohol Dependence, 2013, 132, 541-546.	3.2	49
418	A systematic review of evidence on the association between cocaine use and seizures. Drug and Alcohol Dependence, 2013, 133, 795-804.	3.2	22
419	The contributions of viral hepatitis and alcohol to liver-related deaths in opioid-dependent people. Drug and Alcohol Dependence, 2013, 131, 252-257.	3.2	24
420	Examining the association of NRXN3 SNPs with borderline personality disorder phenotypes in heroin dependent cases and socio-economically disadvantaged controls. Drug and Alcohol Dependence, 2013, 128, 187-193.	3.2	12
421	The persistence of the association between adolescent cannabis use and common mental disorders into young adulthood. Addiction, 2013, 108, 124-133.	3.3	183
422	ANKK1, TTC12, and NCAM1 Polymorphisms and Heroin Dependence. JAMA Psychiatry, 2013, 70, 325.	11.0	66
423	Cannabis Use and the Development and Maintenance of Psychosis. , 2013, , 517-524.		1
424	Mitigating the risk of HIV infection with opioid substitution treatment. Bulletin of the World Health Organization, 2013, 91, 148-149.	3.3	36
425	Mortality among people who inject drugs: a systematic review and meta-analysis. Bulletin of the World Health Organization, 2013, 91, 102-123.	3.3	362
426	How did we arrive at burden of disease estimates for mental and illicit drug use disorders in the Global Burden of Disease Study 2010?. Current Opinion in Psychiatry, 2013, 26, 376-383.	6.3	20
427	Estimating the proportion of prescription opioids that is consumed by people who inject drugs in Australia. Drug and Alcohol Review, 2013, 32, n/a-n/a.	2.1	12
428	Trends in fentanyl prescriptions and fentanyl-related mortality in Australia. Drug and Alcohol Review, 2013, 32, 269-275.	2.1	60
429	Incidence and prevalence of hepatitis C in prisons and other closed settings: Results of a systematic review and meta-analysis. Hepatology, 2013, 58, 1215-1224.	7.3	263
430	The persistence of adolescent binge drinking into adulthood: findings from a 15-year prospective cohort study. BMJ Open, 2013, 3, e003015.	1.9	61
431	The sources of pharmaceuticals for problematic users of benzodiazepines and prescription opioids. Medical Journal of Australia, 2013, 199, 696-699.	1.7	24
432	Recent increase in detection of alprazolam in Victorian heroin-related deaths. Medical Journal of Australia, 2013, 198, 206-209.	1.7	25

#	ARTICLE	IF	CITATIONS
433	Real-time monitoring of Schedule 8 medicines in Australia: evaluation is essential. Medical Journal of Australia, 2013, 198, 80-81.	1.7	32
434	The Global Epidemiology and Contribution of Cannabis Use and Dependence to the Global Burden of Disease: Results from the GBD 2010 Study. PLoS ONE, 2013, 8, e76635.	2.5	235
435	Global Epidemiology of Mental Disorders: What Are We Missing?. PLoS ONE, 2013, 8, e65514.	2.5	148
436	HIV Due to Female Sex Work: Regional and Global Estimates. PLoS ONE, 2013, 8, e63476.	2.5	127
437	Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ, The, 2012, 345, e5945-e5945.	6.0	363
438	Cannabis and progression to other substance use in young adults: findings from a 13-year prospective population-based study. Journal of Epidemiology and Community Health, 2012, 66, e26-e26.	3.7	82
439	The importance of blood-borne viruses in elevated cancer risk among opioid-dependent people: a population-based cohort study. BMJ Open, 2012, 2, e001755.	1.9	32
440	Cannabinoid Receptor Genotype Moderation of the Effects of Childhood Physical Abuse on Anhedonia and Depression. Archives of General Psychiatry, 2012, 69, 732-40.	12.3	75
441	Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet, The, 2012, 379, 55-70.	13.7	1,074
442	Health of the world's adolescents: a synthesis of internationally comparable data. Lancet, The, 2012, 379, 1665-1675.	13.7	408
443	Commentary on <sc>K</sc>elty & <sc>H</sc>ulse (2012): Is the comparison of mortality between patients prescribed implanted or oral naltrexone an unbiased and unconfounded comparison?. Addiction, 2012, 107, 1825-1826.	3.3	2
444	Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2129-2143.	13.7	1,013
445	Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990â€“2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2197-2223.	13.7	7,061
446	Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2095-2128.	13.7	11,038
447	Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990â€“2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2163-2196.	13.7	6,376
448	A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990â€“2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2224-2260.	13.7	9,397
449	Global health metrics and evaluation: a call for abstracts. Lancet, The, 2012, 380, 1722.	13.7	0
450	Injecting drug use and related health behaviours in a small case series of East African migrants in Melbourne. Australian and New Zealand Journal of Public Health, 2012, 36, 586-587.	1.8	5

#	ARTICLE	IF	CITATIONS
451	Transitions from Injection-Drug-Use-Concentrated to Self-Sustaining Heterosexual HIV Epidemics: Patterns in the International Data. PLoS ONE, 2012, 7, e31227.	2.5	37
452	Predicting the Impact of the 2011 Conflict in Libya on Population Mental Health: PTSD and Depression Prevalence and Mental Health Service Requirements. PLoS ONE, 2012, 7, e40593.	2.5	44
453	Commentary on Mehta <i>et al</i>. (2012): Natural history of injecting drug use. Addiction, 2012, 107, 359-360.	3.3	1
454	Pills and pints: Risky drinking and alcoholâ€related harms among regular ecstasy users in Australia. Drug and Alcohol Review, 2012, 31, 273-280.	2.1	16
455	Cross-National Comparisons of Sex Differences in Opportunities to Use Alcohol or Drugs, and the Transitions to Use. Substance Use and Misuse, 2011, 46, 1169-1178.	1.4	28
456	Sex differences amongst dependent heroin users: Histories, clinical characteristics and predictors of other substance dependence. Addictive Behaviors, 2011, 36, 27-36.	3.0	88
457	Mortality among cocaine users: A systematic review of cohort studies. Drug and Alcohol Dependence, 2011, 113, 88-95.	3.2	182
458	What data are available on the extent of illicit drug use and dependence globally? Results of four systematic reviews. Drug and Alcohol Dependence, 2011, 117, 85-101.	3.2	114
459	Post-marketing surveillance of buprenorphine-naloxone in Australia: Diversion, injection and adherence with supervised dosing. Drug and Alcohol Dependence, 2011, 118, 265-273.	3.2	62
460	The association between trauma and delusional-like experiences. Psychiatry Research, 2011, 189, 259-264.	3.3	31
461	Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet, The, 2011, 378, 571-583.	13.7	1,107
462	What are the major drivers of prevalent disability burden in young Australians?. Medical Journal of Australia, 2011, 194, 232-235.	1.7	47
463	P2-416 Estimating the prevalence of hepatitis B infection among people who inject drugs: results from a global systematic review. Journal of Epidemiology and Community Health, 2011, 65, A336-A337.	3.7	2
464	The association between cannabis use and depression: a review of the evidence. , 2011, , 114-128.		4
465	Prescribers' perceptions of the diversion and injection of medication by opioid substitution treatment patients. Drug and Alcohol Review, 2011, 30, 613-620.	2.1	21
466	Definitions related to the use of pharmaceutical opioids: Extramedical use, diversion, nonâ€adherence and aberrant medicationâ€related behaviours. Drug and Alcohol Review, 2011, 30, 236-245.	2.1	107
467	The availability, diversion and injection of pharmaceutical opioids in South Asia. Drug and Alcohol Review, 2011, 30, 246-254.	2.1	48
468	Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction, 2011, 106, 32-51.	3.3	669

#	ARTICLE	IF	CITATIONS
469	Opioid dependence latent structure: two classes with differing severity?. <i>Addiction</i> , 2011, 106, 590-598.	3.3	22
470	The increasing mortality burden of liver disease among opioid-dependent people: cohort study. <i>Addiction</i> , 2011, 106, 2186-2192.	3.3	56
471	Ecstasy Use, Outcome Expectancies, and Sexual Risk Taking. <i>Australian Psychologist</i> , 2011, 46, 219-228.	1.6	4
472	Increasing cancer mortality among opioid-dependent persons in Australia: a new public health challenge for a disadvantaged population. <i>Australian and New Zealand Journal of Public Health</i> , 2011, 35, 220-225.	1.8	51
473	The association between delusional-like experiences, and tobacco, alcohol or cannabis use: a nationwide population-based survey. <i>BMC Psychiatry</i> , 2011, 11, 202.	2.6	46
474	The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia. <i>International Journal of Drug Policy</i> , 2011, 22, 167-171.	3.3	26
475	Cannabis and the increased incidence and persistence of psychosis. <i>BMJ: British Medical Journal</i> , 2011, 342, d719-d719.	2.3	19
476	Outcomes of occasional cannabis use in adolescence: 10-year follow-up study in Victoria, Australia. <i>British Journal of Psychiatry</i> , 2010, 196, 290-295.	2.8	101
477	Investigating the Co-Occurrence of Self-Mutilation and Suicide Attempts among Opioid-Dependent Individuals. <i>Suicide and Life-Threatening Behavior</i> , 2010, 40, 50-62.	1.9	32
478	Meth/amphetamine use and associated HIV: Implications for global policy and public health. <i>International Journal of Drug Policy</i> , 2010, 21, 347-358.	3.3	152
479	Improving the data to strengthen the global response to HIV among people who inject drugs. <i>International Journal of Drug Policy</i> , 2010, 21, 100-102.	3.3	14
480	Mental disorders as risk factors for substance use, abuse and dependence: results from the 10-year follow-up of the National Comorbidity Survey. <i>Addiction</i> , 2010, 105, 1117-1128.	3.3	485
481	The epidemiology of cannabis use and cannabis-related harm in Australia 1993-2007. <i>Addiction</i> , 2010, 105, 1071-1079.	3.3	42
482	WHAT ARE THE POLICY IMPLICATIONS OF THE EVIDENCE ON CANNABIS USE AND PSYCHOSIS?. <i>Addiction</i> , 2010, 105, 1332-1333.	3.3	5
483	Does cannabis use increase the risk of death? Systematic review of epidemiological evidence on adverse effects of cannabis use. <i>Drug and Alcohol Review</i> , 2010, 29, 318-330.	2.1	141
484	Contextualising psychological distress among regular ecstasy users: The importance of sociodemographic factors and patterns of drug use. <i>Drug and Alcohol Review</i> , 2010, 29, 243-249.	2.1	24
485	Early Cannabis Use and Estimated Risk of Later Onset of Depression Spells: Epidemiologic Evidence From the Population-based World Health Organization World Mental Health Survey Initiative. <i>American Journal of Epidemiology</i> , 2010, 172, 149-159.	3.4	64
486	Comparing Probability and Non-Probability Sampling Methods in Ecstasy Research: Implications for the Internet as a Research Tool. <i>Substance Use and Misuse</i> , 2010, 45, 437-450.	1.4	23

#	ARTICLE	IF	CITATIONS
487	Association Between Cannabis Use and Psychosis-Related Outcomes Using Sibling Pair Analysis in a Cohort of Young Adults. Archives of General Psychiatry, 2010, 67, 440.	12.3	211
488	Predictors of social anxiety in an opioid dependent sample and a control sample. Journal of Anxiety Disorders, 2010, 24, 49-54.	3.2	17
489	Is ecstasy a drug of dependence?. Drug and Alcohol Dependence, 2010, 107, 1-10.	3.2	115
490	Evaluating the drug use "gateway" theory using cross-national data: Consistency and associations of the order of initiation of drug use among participants in the WHO World Mental Health Surveys. Drug and Alcohol Dependence, 2010, 108, 84-97.	3.2	228
491	Sexual and injecting risk behaviours among regular ecstasy users. Addictive Behaviors, 2010, 35, 157-160.	3.0	9
492	Systematic review of prospective studies investigating "remission" from amphetamine, cannabis, cocaine or opioid dependence. Addictive Behaviors, 2010, 35, 741-749.	3.0	106
493	Transition to and from injecting drug use among regular ecstasy users. Addictive Behaviors, 2010, 35, 909-912.	3.0	15
494	Adverse health effects of non-medical cannabis use " Authors' reply. Lancet, The, 2010, 375, 197.	13.7	0
495	HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet, The, 2010, 375, 1014-1028.	13.7	629
496	Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet, The, 2010, 376, 285-301.	13.7	382
497	Cannabis: A Clue or a Distraction in the Search for "Causes"™ of Psychosis?. , 2010, , 367-376.		0
498	Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist"antagonist formulation. Medical Journal of Australia, 2009, 191, 161-165.	1.7	40
499	Naloxone for administration by peers in cases of heroin overdose. Medical Journal of Australia, 2009, 191, 469-469.	1.7	23
500	Mental disorders as risk factors for later substance dependence: estimates of optimal prevention and treatment benefits. Psychological Medicine, 2009, 39, 1365-1377.	4.5	102
501	Can the Severity of Dependence Scale Be Usefully Applied to "Ecstasy"™?. Neuropsychobiology, 2009, 60, 137-147.	1.9	58
502	The Epidemiology of Ecstasy Use and Harms in Australia. Neuropsychobiology, 2009, 60, 176-187.	1.9	22
503	The Australian Illicit Drug Reporting System: Monitoring Trends in Illicit Drug Availability, Use and Drug-Related Harm in Australia 1996"2006. Contemporary Drug Problems, 2009, 36, 643-661.	1.6	9
504	Estimating The Level of HIV Prevention Coverage, Knowledge and Protective Behavior Among Injecting Drug Users: What Does The 2008 UNGASS Reporting Round Tell Us?. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 52, S132-S142.	2.1	22

#	ARTICLE	IF	CITATIONS
505	Should Burden of Disease Estimates Include Cannabis Use as a Risk Factor for Psychosis?. PLoS Medicine, 2009, 6, e1000133.	8.4	41
506	GHB in Sydney, Australia, 2000â€“2006: A case study of the EDRS as a strategic early warning system. International Journal of Drug Policy, 2009, 20, 413-417.	3.3	13
507	Child maltreatment as a risk factor for opioid dependence: Comparison of family characteristics and type and severity of child maltreatment with a matched control group. Child Abuse and Neglect, 2009, 33, 343-352.	2.6	100
508	A systematic review of research examining benzodiazepineâ€related mortality. Pharmacoepidemiology and Drug Safety, 2009, 18, 93-103.	1.9	87
509	The Global Diversion of Pharmaceutical Drugs series. Addiction, 2009, 104, 333-334.	3.3	2
510	Are adolescents who moderate their cannabis use at lower risk of later regular and dependent cannabis use?. Addiction, 2009, 104, 806-814.	3.3	21
511	Socioâ€demographic risk factors for alcohol and drug dependence: the 10â€year followâ€up of the national comorbidity survey. Addiction, 2009, 104, 1346-1355.	3.3	138
512	Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: patient characteristics and patterns and predictors of treatment retention. Addiction, 2009, 104, 1363-1372.	3.3	81
513	Estimating the burden of disease attributable to illicit drug use and mental disorders: what is â€Global Burden of Disease 2005â€™ and why does it matter?. Addiction, 2009, 104, 1466-1471.	3.3	20
514	The use of drug detection dogs in Sydney, Australia. Drug and Alcohol Review, 2009, 28, 658-662.	2.1	26
515	Now is the time to take steps to allow peer access to naloxone for heroin overdose in Australia. Drug and Alcohol Review, 2009, 28, 583-585.	2.1	17
516	Crime, drugs and distress: patterns of drug use and harm among criminally involved injecting drug users in Australia. Australian and New Zealand Journal of Public Health, 2009, 33, 223-227.	1.8	37
517	Sociodemographic predictors of transitions across stages of alcohol use, disorders, and remission in the National Comorbidity Survey Replication. Comprehensive Psychiatry, 2009, 50, 299-306.	3.1	83
518	Factors associated with driving under the influence of alcohol and drugs among an Australian sample of regular ecstasy users. Drug and Alcohol Dependence, 2009, 100, 24-31.	3.2	32
519	Geographical clustering of cannabis use: Results from the New Zealand Mental Health Survey 2003â€“2004. Drug and Alcohol Dependence, 2009, 99, 309-316.	3.2	14
520	Further evidence of differences in substance use and dependence between Australia and the United States. Drug and Alcohol Dependence, 2009, 100, 258-264.	3.2	25
521	Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: Risk factors and lives saved. Drug and Alcohol Dependence, 2009, 105, 9-15.	3.2	309
522	Mortality among amphetamine users: A systematic review of cohort studies. Drug and Alcohol Dependence, 2009, 105, 1-8.	3.2	93

#	ARTICLE	IF	CITATIONS
523	Impulsivity and borderline personality as risk factors for suicide attempts among opioid-dependent individuals. <i>Psychiatry Research</i> , 2009, 169, 16-21.	3.3	34
524	Reprint of "Understanding comorbidity between substance use, anxiety and affective disorders: Broadening the research base". <i>Addictive Behaviors</i> , 2009, 34, 795-799.	3.0	15
525	Are non-fatal opioid overdoses misclassified suicide attempts? Comparing the associated correlates. <i>Addictive Behaviors</i> , 2009, 34, 723-729.	3.0	59
526	Understanding comorbidity between substance use, anxiety and affective disorders: Broadening the research base. <i>Addictive Behaviors</i> , 2009, 34, 526-530.	3.0	53
527	Adverse health effects of non-medical cannabis use. <i>Lancet, The</i> , 2009, 374, 1383-1391.	13.7	941
528	Does the "gateway" matter? Associations between the order of drug use initiation and the development of drug dependence in the National Comorbidity Study Replication. <i>Psychological Medicine</i> , 2009, 39, 157-167.	4.5	104
529	Opioid dependence and management. , 2009, , 1-14.		0
530	MDMA: Neurohormonal, Neurocognitive, and Psychobiological Aspects of Recreational Ecstasy. <i>The Open Addiction Journal</i> , 2009, 2, 24-27.	0.5	0
531	The Importance of Timing of Transitions for Risk of Regular Smoking and Nicotine Dependence. <i>Annals of Behavioral Medicine</i> , 2008, 36, 87-92.	2.9	54
532	Depot naltrexone use for opioid dependence in Australia: large-scale use of an unregistered medication in the absence of data on safety and efficacy. <i>Drug and Alcohol Review</i> , 2008, 27, 1-3.	2.1	18
533	Drug use and risk among regular injecting drug users in Australia: does age make a difference?. <i>Drug and Alcohol Review</i> , 2008, 27, 357-360.	2.1	21
534	The effects of the market withdrawal of temazepam gel capsules on benzodiazepine injecting in Sydney, Australia. <i>Drug and Alcohol Review</i> , 2008, 27, 145-151.	2.1	36
535	Crystal methamphetamine smoking among regular ecstasy users in Australia: increases in use and associations with harm. <i>Drug and Alcohol Review</i> , 2008, 27, 292-300.	2.1	25
536	The epidemiology of methamphetamine use and harm in Australia. <i>Drug and Alcohol Review</i> , 2008, 27, 243-252.	2.1	118
537	Methamphetamine: geographic areas and populations at risk, and emerging evidence for effective interventions. <i>Drug and Alcohol Review</i> , 2008, 27, 217-219.	2.1	19
538	Injecting risk behaviour and related harm among men who use performance- and image-enhancing drugs. <i>Drug and Alcohol Review</i> , 2008, 27, 679-686.	2.1	77
539	Estimating the costs of drug-related hospital separations in Australia. <i>Australian and New Zealand Journal of Public Health</i> , 2008, 32, 156-161.	1.8	7
540	A review of the use of US-derived aetiological fractions in an Australian setting for antenatal problems related to cocaine use. <i>Australian and New Zealand Journal of Public Health</i> , 2008, 32, 393-394.	1.8	1

#	ARTICLE	IF	CITATIONS
541	Exposure to opioid maintenance treatment reduces long-term mortality. <i>Addiction</i> , 2008, 103, 462-468.	3.3	161
542	Adolescent cannabis users at 24 years: trajectories to regular weekly use and dependence in young adulthood. <i>Addiction</i> , 2008, 103, 1361-1370.	3.3	158
543	Estimating the size and dynamics of an injecting drug user population and implications for health service coverage: comparison of indirect prevalence estimation methods. <i>Addiction</i> , 2008, 103, 1604-1613.	3.3	27
544	The epidemiology of GHB and ketamine use in an Australian household survey. <i>International Journal of Drug Policy</i> , 2008, 19, 311-316.	3.3	96
545	Australian heroin seizures and the causes of the 2001 heroin shortage. <i>International Journal of Drug Policy</i> , 2008, 19, 293-294.	3.3	1
546	CANNABIS ABUSE AND DEPENDENCE. , 2008, , 117-148.		4
547	Improving targets for the prevention of drug use disorders: Sociodemographic predictors of transitions across drug use stages in the national comorbidity survey replication. <i>Preventive Medicine</i> , 2008, 47, 629-634.	3.4	27
548	Are diagnostic orphans at risk of developing cannabis abuse or dependence?. <i>Drug and Alcohol Dependence</i> , 2008, 92, 86-90.	3.2	23
549	Characteristics of drug-related hospital separations in Australia. <i>Drug and Alcohol Dependence</i> , 2008, 92, 149-155.	3.2	28
550	Assessment of cocaine and other drug dependence in the general population: "Gated" versus "ungated" approaches. <i>Drug and Alcohol Dependence</i> , 2008, 93, 227-232.	3.2	35
551	Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. <i>Lancet</i> , The, 2008, 372, 1733-1745.	13.7	1,107
552	Drug Dependence and Associated Risks Among Female Street-Based Sex Workers in the Greater Sydney Area, Australia. <i>Substance Use and Misuse</i> , 2008, 43, 1202-1217.	1.4	22
553	The adverse effects of cannabinoids: implications for use of medical marijuana. <i>Cmaj</i> , 2008, 178, 1685-1686.	2.0	28
554	Cannabis use and the risk of developing a psychotic disorder. <i>World Psychiatry</i> , 2008, 7, 68-71.	10.4	109
555	Response to Brewer. <i>Drug and Alcohol Review</i> , 2008, 27, 448-449.	2.1	0
556	Toward a Global View of Alcohol, Tobacco, Cannabis, and Cocaine Use: Findings from the WHO World Mental Health Surveys. <i>PLoS Medicine</i> , 2008, 5, e141.	8.4	629
557	Impact of Drug Market Changes on Substance-Using Pregnant Women in Three Key Sydney Drug Markets. <i>Women and Health</i> , 2007, 44, 93-105.	1.0	2
558	Cannabis-Induced Psychosis among Aboriginal People in the Northwest Territories. <i>Canadian Journal of Psychiatry</i> , 2007, 52, 475-476.	1.9	0

#	ARTICLE	IF	CITATIONS
559	Prevalence and correlates of cannabis use in developed and developing countries. <i>Current Opinion in Psychiatry</i> , 2007, 20, 393-397.	6.3	139
560	The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10-month prospective study. <i>Psychological Medicine</i> , 2007, 37, 927-934.	4.5	79
561	Epidemiological patterns of extra-medical drug use in the United States: Evidence from the National Comorbidity Survey Replication, 2001â€“2003. <i>Drug and Alcohol Dependence</i> , 2007, 90, 210-223.	3.2	86
562	A descriptive epidemiology of substance use and substance use disorders in Nigeria during the early 21st century. <i>Drug and Alcohol Dependence</i> , 2007, 91, 1-9.	3.2	106
563	Predictors of frequent use of amphetamine type stimulants among HIV-negative gay men in Sydney, Australia. <i>Drug and Alcohol Dependence</i> , 2007, 91, 260-268.	3.2	52
564	UK classification of cannabis: is a change needed and why?. <i>Lancet, The</i> , 2007, 370, 1541.	13.7	3
565	Opioid overdose deaths can occur in patients with naltrexone implants. <i>Medical Journal of Australia</i> , 2007, 186, 152-153.	1.7	41
566	Opioid overdose deaths can occur in patients with naltrexone implants. <i>Medical Journal of Australia</i> , 2007, 187, 56-57.	1.7	19
567	Hospital separations for cannabisâ€™and methamphetamineâ€™related psychotic episodes in Australia. <i>Medical Journal of Australia</i> , 2007, 186, 342-345.	1.7	47
568	Assessing cannabis dependence in community surveys: methodological issues. <i>International Journal of Methods in Psychiatric Research</i> , 2007, 16, 43-51.	2.1	31
569	Case ascertainment of alcohol dependence in general population surveys: â€™gatedâ€™™ versus â€™ungatedâ€™™ approaches. <i>International Journal of Methods in Psychiatric Research</i> , 2007, 16, 111-123.	2.1	35
570	PROJECTING THE IMPACT OF CHANGES IN CANNABIS USE UPON SCHIZOPHRENIA IN ENGLAND AND WALES: THE ROLE OF ASSUMPTIONS AND BALANCE IN FRAMING AN EVIDENCE-BASED CANNABIS POLICY. <i>Addiction</i> , 2007, 102, 515-516.	3.3	4
571	The predictors and consequences of adolescent amphetamine use: findings from the Victoria Adolescent Health Cohort Study. <i>Addiction</i> , 2007, 102, 1076-1084.	3.3	66
572	Who are the new amphetamine users? A 10â€™year prospective study of young Australians. <i>Addiction</i> , 2007, 102, 1269-1279.	3.3	37
573	Suicidal behaviour and associated risk factors among opioidâ€™dependent individuals: a caseâ€™control study. <i>Addiction</i> , 2007, 102, 1933-1941.	3.3	93
574	Regulating opioid prescribing to provide access to effective treatment while minimizing diversion: an overdue topic for research. <i>Addiction</i> , 2007, 102, 1685-1688.	3.3	16
575	Affective disorders, anxiety disorders and psychological distress in non-drinkers. <i>Journal of Affective Disorders</i> , 2007, 99, 165-172.	4.1	23
576	Mortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial records. <i>Drug and Alcohol Review</i> , 2007, 26, 405-410.	2.1	56

#	ARTICLE	IF	CITATIONS
577	Examining links between cocaine use and street-based sex work in New South Wales, Australia. Journal of Sex Research, 2006, 43, 107-114.	2.5	7
578	Risk and benefit perceptions of party drug use. Addictive Behaviors, 2006, 31, 137-142.	3.0	43
579	Substance use, dependence and treatment seeking in the United States and Australia: A cross-national comparison. Drug and Alcohol Dependence, 2006, 81, 149-155.	3.2	80
580	Prevalence of injecting drug use and associated risk behavior among regular ecstasy users in Australia. Drug and Alcohol Dependence, 2006, 83, 210-217.	3.2	20
581	What are the Policy Implications of the Evidence on Cannabis and Psychosis?. Canadian Journal of Psychiatry, 2006, 51, 566-574.	1.9	41
582	Why illicit drug-related deaths matter. , 2006, , 1-9.		0
583	Mortality and trauma. , 2006, , 96-110.		0
584	Reducing drug-related mortality. , 2006, , 111-134.		0
585	Mortality amongst illicit drug users. , 2006, , 20-41.		4
586	Is Cannabis Use a Contributory Cause of Psychosis?. Canadian Journal of Psychiatry, 2006, 51, 556-565.	1.9	105
587	The "lessons" of the Australian "heroin shortage". Substance Abuse Treatment, Prevention, and Policy, 2006, 1, 11.	2.2	47
588	CANADIAN HEROIN SUPPLY AND THE AUSTRALIAN "HEROIN SHORTAGE". Addiction, 2006, 101, 1667-1668.	3.3	1
589	Documenting the heroin shortage in New South Wales. Drug and Alcohol Review, 2006, 25, 297-305.	2.1	21
590	Changes in the initiation of heroin use after a reduction in heroin supply. Drug and Alcohol Review, 2006, 25, 307-313.	2.1	30
591	Trends in morphine prescriptions, illicit morphine use and associated harms among regular injecting drug users in Australia. Drug and Alcohol Review, 2006, 25, 403-412.	2.1	68
592	Reflections on the development and implementation of an early warning system for ecstasy and related drug markets in Australia. Drug and Alcohol Review, 2006, 25, 445-449.	2.1	11
593	Methods estimating the prevalence of problem drug use. International Journal of Drug Policy, 2006, 17, 154-158.	3.3	7
594	Driving, drug use behaviour and risk perceptions of nightclub attendees in Victoria, Australia. International Journal of Drug Policy, 2006, 17, 41-46.	3.3	48

#	ARTICLE	IF	CITATIONS
595	A survey of regular ecstasy usersâ€™ knowledge and practices around determining pill content and purity: Implications for policy and practice. <i>International Journal of Drug Policy</i> , 2006, 17, 464-472.	3.3	37
596	Using intervention time series analyses to assess the effects of imperfectly identifiable natural events: a general method and example. <i>BMC Medical Research Methodology</i> , 2006, 6, 16.	3.1	67
597	Posttraumatic stress disorder among female street-based sex workers in the greater Sydney area, Australia. <i>BMC Psychiatry</i> , 2006, 6, 24.	2.6	71
598	Identification and quantification of change in Australian illicit drug markets. <i>BMC Public Health</i> , 2006, 6, 200.	2.9	7
599	Reasons for Cannabis use in Psychosis. <i>Australian and New Zealand Journal of Psychiatry</i> , 2006, 40, 570-574.	2.3	107
600	Using cohort studies to estimate mortality among injecting drug users that is not attributable to AIDS. <i>Sexually Transmitted Infections</i> , 2006, 82, iii56-iii63.	1.9	81
601	Alcohol Use and Risk Taking Among Regular Ecstasy Users. <i>Substance Use and Misuse</i> , 2006, 41, 1095-1109.	1.4	38
602	Reasons for cannabis use in psychosis. <i>Australian and New Zealand Journal of Psychiatry</i> , 2006, 40, 570-574.	2.3	2
603	Drug-related aggression among injecting drug users. <i>NSW Public Health Bulletin</i> , 2006, 17, 12.	0.3	1
604	How common is comorbidity and why does it occur?. <i>Australian Psychologist</i> , 2005, 40, 81-87.	1.6	9
605	Gender differences among regular injecting drug users in Sydney, Australia, 1996-2003. <i>Drug and Alcohol Review</i> , 2005, 24, 353-358.	2.1	20
606	The definition of opioid-related deaths in Australia: implications for surveillance and policy. <i>Drug and Alcohol Review</i> , 2005, 24, 401-409.	2.1	18
607	The management of alcohol, tobacco and illicit drug use problems by general practitioners in Australia. <i>Drug and Alcohol Review</i> , 2005, 24, 499-506.	2.1	14
608	Evaluating explanations of the Australian â€˜heroin shortageâ€™. <i>Addiction</i> , 2005, 100, 459-469.	3.3	105
609	Effects of a sustained heroin shortage in three Australian States. <i>Addiction</i> , 2005, 100, 908-920.	3.3	121
610	MAPPING THE CONSEQUENCES OF AN UNANTICIPATED DRUG SUPPLY CHANGE OF UNCERTAIN ORIGINS: RESPONSE TO THE COMMENTARIES. <i>Addiction</i> , 2005, 100, 930-932.	3.3	3
611	Patterns of illicit drug use in NSW, Australia following a reduction in heroin supply. <i>International Journal of Drug Policy</i> , 2005, 16, 300-307.	3.3	11
612	Recent trends in heroin supply to markets in Australia, the United States and Western Europe. <i>International Journal of Drug Policy</i> , 2005, 16, 293-299.	3.3	18

#	ARTICLE	IF	CITATIONS
613	Was an increase in cocaine use among injecting drug users in New South Wales, Australia, accompanied by an increase in violent crime?. BMC Public Health, 2005, 5, 40.	2.9	21
614	Drug use and risk behaviours among injecting drug users: a comparison between sex workers and non-sex workers in Sydney, Australia. Harm Reduction Journal, 2005, 2, 7.	3.2	8
615	The effect of a reduction in heroin supply on fatal and non-fatal drug overdoses in New South Wales, Australia. Medical Journal of Australia, 2005, 182, 20-23.	1.7	45
616	Recent Trends in the Use of "Club Drugs": An Australian Review. Substance Use and Misuse, 2005, 40, 1241-1256.	1.4	90
617	Underlying causes of cocaine, amphetamine and opioid related deaths in Australia. Journal of Clinical Forensic and Legal Medicine, 2005, 12, 187-195.	0.8	27
618	The impact of illicit drug market changes on health agency operations in Sydney, Australia. Journal of Substance Abuse Treatment, 2005, 28, 35-40.	2.8	12
619	The impact of a reduction in drug supply on demand for and compliance with treatment for drug dependence. Drug and Alcohol Dependence, 2005, 79, 129-135.	3.2	29
620	Age differentials in the impacts of reduced heroin: Effects of a "heroin shortage" in NSW, Australia. Drug and Alcohol Dependence, 2005, 79, 397-404.	3.2	13
621	The impact of changes to heroin supply on blood-borne virus notifications and injecting related harms in New South Wales, Australia. BMC Public Health, 2005, 5, 84.	2.9	8
622	Drug use and risk behaviour among regular ecstasy users: Does sexuality make a difference?. Culture, Health and Sexuality, 2005, 7, 599-614.	1.8	39
623	The effects of restricting publicly subsidised temazepam capsules on benzodiazepine use among injecting drug users in Australia. Medical Journal of Australia, 2004, 181, 300-304.	1.7	30
624	The association between cannabis use and depression: a review of the evidence. , 2004, , 54-74.		0
625	Is there a specific "cannabis psychosis"? , 2004, , 89-100.		15
626	The Effect of a Reduction in Heroin Supply in Australia upon Drug Distribution and Acquisitive Crime. British Journal of Criminology, 2004, 45, 2-24.	2.1	45
627	Effects of reduction in heroin supply on injecting drug use: analysis of data from needle and syringe programmes. BMJ: British Medical Journal, 2004, 329, 428-429.	2.3	33
628	Reliability of heroin users' reports of drug use behaviour using a 24 month timeline follow-back technique to assess the impact of the Australian heroin shortage. Addiction Research and Theory, 2004, 12, 433-443.	1.9	24
629	Distribution of Major Health Risks: Findings from the Global Burden of Disease Study. PLoS Medicine, 2004, 1, e27.	8.4	206
630	Patterns of ecstasy use in Australia: findings from a national household survey. Addiction, 2004, 99, 187-195.	3.3	83

#	ARTICLE	IF	CITATIONS
631	Changes in patterns of drug use among injecting drug users following changes in the availability of heroin in New South Wales, Australia. <i>Drug and Alcohol Review</i> , 2004, 23, 287-294.	2.1	32
632	Cannabis use and psychotic disorders: an update. <i>Drug and Alcohol Review</i> , 2004, 23, 433-443.	2.1	88
633	The external validity of results derived from ecstasy users recruited using purposive sampling strategies. <i>Drug and Alcohol Dependence</i> , 2004, 73, 33-40.	3.2	107
634	Contemplating drug monitoring systems in the light of Australia's "heroin shortage". <i>Drug and Alcohol Review</i> , 2003, 22, 3-6.	2.1	2
635	Patterns of co-morbidity between alcohol use and other substance use in the Australian population. <i>Drug and Alcohol Review</i> , 2003, 22, 7-13.	2.1	61
636	"Crystal meth" use among polydrug users in Sydney's dance party subculture: characteristics, use patterns and associated harms. <i>International Journal of Drug Policy</i> , 2003, 14, 17-24.	3.3	73
637	The prevalence and correlates of gamma-hydroxybutyrate (GHB) overdose among Australian users. <i>Addiction</i> , 2003, 98, 199-204.	3.3	72
638	Methadone-related and heroin-related deaths among opiate users: methadone helps save lives. <i>Addiction</i> , 2003, 98, 387-388.	3.3	16
639	A longitudinal study of the effects of adolescent cannabis use on high school completion. <i>Addiction</i> , 2003, 98, 685-692.	3.3	145
640	Exploring the association between cannabis use and depression. <i>Addiction</i> , 2003, 98, 1493-1504.	3.3	470
641	The ratio of non-fatal to fatal heroin overdose. <i>Addiction</i> , 2003, 98, 1169-1171.	3.3	95
642	Changes in patterns of drug injection concurrent with a sustained reduction in the availability of heroin in Australia. <i>Drug and Alcohol Dependence</i> , 2003, 70, 275-286.	3.2	108
643	Testing hypotheses about the relationship between cannabis use and psychosis. <i>Drug and Alcohol Dependence</i> , 2003, 71, 37-48.	3.2	242
644	Medical Marijuana Initiatives. <i>CNS Drugs</i> , 2003, 17, 689-697.	5.9	33
645	The link between cannabis use and psychosis: furthering the debate. <i>Psychological Medicine</i> , 2003, 33, 3-6.	4.5	34
646	GHB: Un análisis. <i>Revista De Psicologia De La Salud</i> , 2003, 15, 167.	0.5	1
647	Cannabis use and mental health in young people: cohort study. <i>BMJ: British Medical Journal</i> , 2002, 325, 1195-1198.	2.3	809
648	Selected major risk factors and global and regional burden of disease. <i>Lancet, The</i> , 2002, 360, 1347-1360.	13.7	2,943

#	ARTICLE	IF	CITATIONS
649	GHB use among Australians: characteristics, use patterns and associated harm. Drug and Alcohol Dependence, 2002, 67, 89-94.	3.2	135
650	“Diagnostic orphans” among young adult cannabis users: persons who report dependence symptoms but do not meet diagnostic criteria. Drug and Alcohol Dependence, 2002, 67, 205-212.	3.2	48
651	Cannabis and psychosis. Current Psychiatry Reports, 2002, 4, 191-196.	4.5	64
652	Cannabis dependence in young adults: an Australian population study. Addiction, 2002, 97, 187-194.	3.3	142
653	CDT, GGT, and AST As Markers of Alcohol Use: The WHO/ISBRA Collaborative Project. Alcoholism: Clinical and Experimental Research, 2002, 26, 332-339.	2.4	247
654	Substance use disorders in an Australian community survey. Drug and Alcohol Review, 2002, 21, 275-280.	2.1	6
655	The emergence of potent forms of methamphetamine in Sydney, Australia: a case study of the IDRS as a strategic early warning system. Drug and Alcohol Review, 2002, 21, 341-348.	2.1	77
656	CDT, GGT, and AST As Markers of Alcohol Use: The WHO/ISBRA Collaborative Project. Alcoholism: Clinical and Experimental Research, 2002, 26, 332-339.	2.4	0
657	The relationship between cannabis use and other substance use in the general population. Drug and Alcohol Dependence, 2001, 64, 319-327.	3.2	140
658	Allowing the medical use of cannabis. Medical Journal of Australia, 2001, 175, 39-40.	1.7	14
659	The association between psychosis and problematical drug use among Australian adults: findings from the National Survey of Mental Health and Well-Being. Psychological Medicine, 2001, 31, 659-668.	4.5	167
660	The relationship between cannabis use, depression and anxiety among Australian adults: findings from the National Survey of Mental Health and Well-Being. Social Psychiatry and Psychiatric Epidemiology, 2001, 36, 219-227.	3.1	120
661	Alcohol, cannabis and tobacco use among Australians: a comparison of their associations with other drug use and use disorders, affective and anxiety disorders, and psychosis. Addiction, 2001, 96, 1603-1614.	3.3	263
662	Ambulance calls to suspected overdoses: New South Wales patterns July 1997 to June 1999. Australian and New Zealand Journal of Public Health, 2001, 25, 447-450.	1.8	19
663	The validity of an Australian modification of the AUDIT questionnaire. Drug and Alcohol Review, 2001, 20, 143-154.	2.1	23
664	Ambulance calls to suspected overdoses: New South Wales patterns July 1997 to June 1999. Australian and New Zealand Journal of Public Health, 2001, 25, 447-450.	1.8	0
665	Cannabis Use and Psychosis: A Review of Clinical and Epidemiological Evidence. Australian and New Zealand Journal of Psychiatry, 2000, 34, 26-34.	2.3	160
666	Cohort trends in youth suicide in Australia 1964-1997. Australian and New Zealand Journal of Psychiatry, 2000, 34, 408-412.	2.3	3

#	ARTICLE	IF	CITATIONS
667	Cohort trends in the age of initiation of drug use in Australia. Australian and New Zealand Journal of Public Health, 2000, 24, 421-426.	1.8	105
668	How many dependent heroin users are there in Australia?. Medical Journal of Australia, 2000, 173, 528-531.	1.7	133
669	Cohort Trends in Youth Suicide in Australia 1964-1997. Australian and New Zealand Journal of Psychiatry, 2000, 34, 408-412.	2.3	21
670	Interventions for people with alcohol use disorders and an intellectual disability: A review of the literature. Journal of Intellectual and Developmental Disability, 2000, 25, 135-146.	1.6	50
671	Alcohol- and Drug-Use Disorders in Australia: Implications of the National Survey of Mental Health and Wellbeing. Australian and New Zealand Journal of Psychiatry, 2000, 34, 206-213.	2.3	193
672	Trends in opiate-related deaths in the United Kingdom and Australia, 1985-1995. Drug and Alcohol Dependence, 2000, 57, 247-254.	3.2	86
673	Alcohol- and drug-use disorders in Australia: implications of the National Survey of Mental Health and Wellbeing. Australian and New Zealand Journal of Psychiatry, 2000, 34, 206-213.	2.3	128
674	Opioid overdose mortality in Australia, 1964-1997: birth-cohort trends. Medical Journal of Australia, 1999, 171, 34-37.	1.7	65
675	The 12-month prevalence of substance use and ICD-10 substance use disorders in Australian adults: findings from the National Survey of Mental Health and Well-Being. Addiction, 1999, 94, 1541-1550.	3.3	145
676	The Decline in Alcohol Disorders with Age: Causes and Implications. Australasian Journal on Ageing, 1998, 17, 158-159.	0.9	1
677	Schizophrenia secondary to cannabis use. , 0, , 169-178.		0
678	Substance Use and Mental Health in Longitudinal Perspective. , 0, , 43-51.		20
679	Mortality and suicide. , 0, , 80-95.		0
680	The global epidemiology of illicit drug use. , 0, , 10-19.		0
681	Mortality and drug overdose. , 0, , 42-66.		0
682	Illicit drug use and disease. , 0, , 67-79.		0
683	What are the policy implications of the evidence on cannabis and psychosis?. , 0, , 55-65.		1
684	Drug-Use Disorders. , 0, , 243-262.		3

#	ARTICLE	IF	CITATIONS
685	Genome-wide association study of phenotypes measuring progression from first cocaine or opioid use to dependence reveals novel risk genes. Exploration of Medicine, 0, , .	1.5	0
686	Quantitative Data Analysis. , 0, , 163-183.		17
687	Addictions. , 0, , .		1